Data / Research funding / Massachusetts / Dana-Farber Cancer Inst
Dana-Farber Cancer Inst: 461 NIH awards ($821.3M) and 2 NSF awards ($202.7K), fiscal years 2021 to 2026
Dana-Farber Cancer Inst in Boston, MA is funded under 461 NIH awards ($821.3M) and 2 NSF awards ($202.7K) in the NIH and NSF award files, read 2026-11-03. NIH fiscal years 2021 to 2025; NSF fiscal years 2022 to 2026.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- UEI
- DPMGH9MG1X67
- State
- Massachusetts
Awards
463 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| NCI Early Career Cancer Clinical Investigator Award | NIH | National Cancer Institute | 2021 to 2025 | $65,560,307 | March 10, 1997 | November 30, 2026 | EBERT, BENJAMIN LEVINE | reporter.nih.gov |
| ECOG-ACRIN Network Group Statistics and Data Management Center | NIH | National Cancer Institute | 2021 to 2025 | $40,175,470 | April 29, 2014 | February 28, 2026 | GRAY, ROBERT J | reporter.nih.gov |
| Human Tumor Atlas Network: Data Coordinating Center | NIH | National Cancer Institute | 2023 to 2025 | $13,148,220 | September 30, 2018 | August 31, 2029 | GENTLEMAN, ROBERT C | reporter.nih.gov |
| Biology and structure of pMHC receptors functioning as mechanosensors in the [alpha][beta] T-cell lineage | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,386,136 | July 29, 2020 | July 31, 2030 | REINHERZ, ELLIS L | reporter.nih.gov |
| Mechanisms and Therapy of Chronic Graft-vs.-Host Disease | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $10,320,200 | September 15, 2022 | August 31, 2027 | CUTLER, COREY S | reporter.nih.gov |
| Development of Novel Therapeutic Strategies in Human Leukemias | NIH | National Cancer Institute | 2021 to 2025 | $9,780,487 | April 25, 1997 | August 31, 2030 | EBERT, BENJAMIN LEVINE | reporter.nih.gov |
| Dana Farber/Harvard Cancer Center Specialized Program of Research Excellence in Breast Cancer | NIH | National Cancer Institute | 2021 to 2025 | $9,465,449 | September 17, 2013 | July 31, 2030 | POLYAK, KORNELIA | reporter.nih.gov |
| Integrative Oncogenomics of Multiple Myeloma | NIH | National Cancer Institute | 2021 to 2025 | $9,247,248 | December 1, 2011 | July 31, 2028 | MUNSHI, NIKHIL C. | reporter.nih.gov |
| Dana Farber/Harvard Cancer Center SPORE in Lung Cancer | NIH | National Cancer Institute | 2022 to 2025 | $9,074,410 | August 1, 2022 | July 31, 2027 | BARBIE, DAVID A | reporter.nih.gov |
| Dana Farber/Harvard Cancer Center Ovarian Cancer SPORE grant | NIH | National Cancer Institute | 2021 to 2024 | $8,975,063 | August 3, 2020 | July 31, 2025 | D'ANDREA, ALAN D. | reporter.nih.gov |
| 2/2 The University of Massachusetts, Boston - Dana-Farber/Harvard Cancer Center U54 Comprehensive Partnership for Cancer Disparities Research | NIH | National Cancer Institute | 2021 to 2025 | $8,436,106 | September 27, 2010 | August 31, 2026 | ABEL, GREGORY ALAN | reporter.nih.gov |
| Immune Modulation After Allogeneic HCT | NIH | National Cancer Institute | 2021 to 2023 | $8,308,700 | August 14, 2019 | July 31, 2025 | SOIFFER, ROBERT JON | reporter.nih.gov |
| Molecular phenotyping of ~100,000 coding variants across Mendelian disease genes | NIH | National Human Genome Research Institute | 2021 to 2025 | $8,292,746 | August 23, 2021 | May 31, 2026 | VIDAL, MARC | reporter.nih.gov |
| Comprehensive dissection of the CLL genome & phenome to improve patient outcomes | NIH | National Cancer Institute | 2021 to 2025 | $8,043,507 | September 1, 2016 | August 31, 2026 | WU, CATHERINE JU-YING | reporter.nih.gov |
| DF/HCC Prostate SPORE | NIH | National Cancer Institute | 2023 to 2025 | $7,058,769 | September 1, 2023 | August 31, 2028 | BELTRAN, HIMISHA | reporter.nih.gov |
| Dana-Farber/Harvard Cancer Center Experimental Therapeutics Clinical Trials Network Site (DF/HCC ETCTN Site) | NIH | National Cancer Institute | 2021 to 2025 | $7,018,946 | March 13, 2014 | February 28, 2027 | SHAPIRO, GEOFFREY I. | reporter.nih.gov |
| New therapeutic vulnerabilities in breast cancer | NIH | National Cancer Institute | 2021 to 2024 | $6,857,044 | September 11, 2020 | May 31, 2026 | POLYAK, KORNELIA | reporter.nih.gov |
| SPORE in Multiple Myeloma | NIH | National Cancer Institute | 2021 to 2023 | $6,771,597 | September 16, 2003 | May 31, 2025 | ANDERSON, KENNETH C. | reporter.nih.gov |
| Bioconductor: An Open-Source, Open-Development Computing Resource for Genomics | NIH | National Human Genome Research Institute | 2021 to 2025 | $6,327,693 | September 28, 2006 | February 28, 2027 | IRIZARRY, RAFAEL ANGEL | reporter.nih.gov |
| The Cellular Geography of Therapeutic Resistance in Cancer | NIH | National Cancer Institute | 2021 to 2023 | $6,163,685 | April 4, 2023 | August 31, 2024 | VAN ALLEN, ELIEZER M | reporter.nih.gov |
| Dana Farber/ Harvard Cancer Center SPORE in Gastrointestinal Cancer | NIH | National Cancer Institute | 2021 to 2023 | $5,953,561 | April 1, 2007 | May 31, 2025 | SELLERS, WILLIAM R | reporter.nih.gov |
| Targeting Replication Stress and DNA Damage Response in Uterine Cancer | NIH | National Cancer Institute | 2024 to 2025 | $5,927,036 | May 1, 2024 | April 30, 2029 | MATULONIS, URSULA ANNE | reporter.nih.gov |
| Cancer Immune Monitoring and Analysis Center | NIH | National Cancer Institute | 2023 to 2025 | $5,746,876 | September 30, 2017 | June 30, 2028 | WU, CATHERINE JU-YING | reporter.nih.gov |
| Myeloma multidimensional precancer atlas | NIH | National Cancer Institute | 2024 to 2025 | $5,566,942 | September 18, 2024 | August 31, 2029 | GHOBRIAL, IRENE M. | reporter.nih.gov |
| NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care | NIH | National Cancer Institute | 2021 to 2025 | $5,422,908 | March 5, 2019 | February 28, 2026 | BURSTEIN, HAROLD JOHN | reporter.nih.gov |
| Targeting intratumor heterogeneity in breast cancer | NIH | National Cancer Institute | 2021 to 2025 | $5,301,919 | August 1, 2015 | July 31, 2029 | POLYAK, KORNELIA | reporter.nih.gov |
| Lung Adenocarcinoma: From Genome Alterations to Therapeutic Discovery | NIH | National Cancer Institute | 2021 to 2025 | $5,246,301 | August 1, 2015 | July 31, 2028 | MEYERSON, MATTHEW L. | reporter.nih.gov |
| Structure, mechanism, and pharmacology of BRAF and its partners in the RAS/RAF/MAP kinase pathway | NIH | National Cancer Institute | 2021 to 2025 | $5,243,880 | September 1, 2019 | August 31, 2026 | ECK, MICHAEL J | reporter.nih.gov |
| Dissecting and Targeting Deregulated Mitochondrial Apoptosis in Human Cancer | NIH | National Cancer Institute | 2021 to 2025 | $5,186,053 | August 24, 2015 | July 31, 2028 | WALENSKY, LOREN DAVID | reporter.nih.gov |
| Identification of Novel Oncogenic Signaling Pathways using Viral Perturbations | NIH | National Cancer Institute | 2021 to 2025 | $5,173,906 | August 8, 2019 | July 31, 2026 | DECAPRIO, JAMES A. | reporter.nih.gov |
| Genomic and Genomic Variation in Prostate Cancer | NIH | National Cancer Institute | 2022 to 2025 | $5,164,514 | January 7, 2022 | April 30, 2027 | REBBECK, TIMOTHY RICHARD | reporter.nih.gov |
| Reading mitochondrial apoptotic signaling to identify active cancer therapeutics | NIH | National Cancer Institute | 2021 to 2025 | $5,159,959 | August 1, 2019 | September 29, 2025 | LETAI, ANTHONY G | reporter.nih.gov |
| Maximizing the Effectiveness of PI3K Inhibitors in the Treatment of Pten null Cancers | NIH | National Cancer Institute | 2021 to 2025 | $5,154,412 | September 1, 2019 | August 31, 2026 | ROBERTS, THOMAS M | reporter.nih.gov |
| Informed Combination Strategies for Peripheral T-cell Lymphomas | NIH | National Cancer Institute | 2021 to 2023 | $5,129,346 | September 1, 2019 | August 31, 2024 | KNOECHEL, BIRGIT | reporter.nih.gov |
| Radiation Oncology at the Interface of Pediatric Cancer Biology and Data Science | NIH | National Cancer Institute | 2023 to 2025 | $5,032,714 | September 19, 2023 | August 31, 2028 | HAAS-KOGAN, DAPHNE A. | reporter.nih.gov |
| Integrating targeted therapy and immunotherapy to break through cancer | NIH | National Cancer Institute | 2021 to 2025 | $5,025,838 | September 1, 2016 | August 31, 2030 | ZHAO, JEAN | reporter.nih.gov |
| The von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer: Insights into Oxygen Sensing and Treating Cancers Caused by Undruggable Mutations | NIH | National Cancer Institute | 2021 to 2025 | $4,888,860 | September 1, 2016 | August 31, 2030 | KAELIN, WILLIAM G. | reporter.nih.gov |
| Identification of Metabolic and Immune Deficits in the Aged Population and Their Restoration to Achieve Youthful Anti-Influenza Vaccine Responsiveness | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,757,817 | November 22, 2021 | October 31, 2026 | MARASCO, WAYNE A. | reporter.nih.gov |
| RNA-based HIV-1 chimera vaccines encoding a trimerizing host self-protein protomer linked to a viral MPER-TM segment | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $4,613,193 | April 1, 2024 | March 31, 2029 | REINHERZ, ELLIS L | reporter.nih.gov |
| Administrative supplement to Improving Advance Care Planning in Oncology: A Pragmatic, Cluster-Randomized Trial Integrating Patient Videosand Clinician Communication Training | NIH | National Institute on Aging | 2021 to 2025 | $4,298,226 | July 1, 2018 | June 30, 2026 | TULSKY, JAMES A. | reporter.nih.gov |
| Molecular Prediction of Myeloma Initiation Molecular Prediction of Myeloma Initiation | NIH | National Cancer Institute | 2022 to 2025 | $4,108,272 | September 6, 2022 | August 31, 2029 | GHOBRIAL, IRENE M. | reporter.nih.gov |
| Altered metabolism and machine learning for pancreatic cancer early detection | NIH | National Cancer Institute | 2021 to 2025 | $4,100,528 | September 16, 2022 | August 31, 2027 | WOLPIN, BRIAN MATTHEW | reporter.nih.gov |
| Stromal modulation of pancreatic cancer malignant cell state and therapeutic sensitivity | NIH | National Cancer Institute | 2022 to 2025 | $4,096,241 | September 19, 2022 | August 31, 2027 | HAHN, WILLIAM C. | reporter.nih.gov |
| Development of Combination Therapies to Delay/Prevent Acquired Drug Resistance | NIH | National Cancer Institute | 2021 to 2024 | $4,095,825 | September 10, 2018 | August 31, 2025 | JANNE, PASI A | reporter.nih.gov |
| The role of clonal hematopoiesis in the development and therapy of myeloid malignancies | NIH | National Cancer Institute | 2021 to 2024 | $3,926,618 | August 15, 2020 | November 1, 2024 | EBERT, BENJAMIN LEVINE | reporter.nih.gov |
| Dissecting CCL5 contribution to antigen specific T cell responses in head and neck cancers | NIH | National Institute of Dental & Craniofacial Research | 2025 | $3,742,682 | August 21, 2025 | August 20, 2029 | UPPALURI, RAVINDRA | reporter.nih.gov |
| HIV-1 Preintegration Trafficking and Nuclear Localization | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,586,576 | January 15, 2003 | May 31, 2027 | ENGELMAN, ALAN N. | reporter.nih.gov |
| Biochemical Mechanism of HIV DNA Integration | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,536,253 | June 1, 2025 | May 31, 2030 | ENGELMAN, ALAN N. | reporter.nih.gov |
| Evolution of gliomas during treatment and resistance | NIH | National Cancer Institute | 2021 to 2025 | $3,464,231 | April 1, 2015 | June 30, 2026 | BEROUKHIM, RAMEEN | reporter.nih.gov |
| Molecular prediction of myeloma in African Americans | NIH | National Cancer Institute | 2022 to 2025 | $3,450,221 | September 12, 2022 | August 31, 2027 | MARINAC, CATHERINE | reporter.nih.gov |
| Structure-activity relationships governing mammalian SWI/SNF chromatin remodeling activity as a function of chromatin state | NIH | National Cancer Institute | 2021 to 2025 | $3,409,205 | April 1, 2021 | March 31, 2026 | KADOCH, CIGALL | reporter.nih.gov |
| Elucidation of the genetic mechanisms driving prostate tumorigenesis through integrative computational and functional approaches | NIH | National Cancer Institute | 2021 to 2025 | $3,352,278 | March 2, 2021 | February 28, 2027 | FREEDMAN, MATTHEW L | reporter.nih.gov |
| Elucidating prostate cancer risk mechanisms through large-scale cistrome wide association studies | NIH | National Cancer Institute | 2022 to 2025 | $3,342,109 | September 1, 2022 | August 31, 2027 | FREEDMAN, MATTHEW L | reporter.nih.gov |
| A Stakeholder Informed Randomized Trial of Pretest Video Education vs Standard Genetic Counseling for Cancer Patients: Evaluating the Impact on Patients, Providers and Practices | NIH | National Human Genome Research Institute | 2021 to 2024 | $3,208,986 | September 22, 2021 | June 30, 2026 | RANA, HUMA Q | reporter.nih.gov |
| Conformational Landscape of the HIV-1 Envelope Glycoproteins | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,207,950 | February 15, 2016 | March 31, 2027 | SODROSKI, JOSEPH G | reporter.nih.gov |
| PGC1alpha Pathway: Novel Intracellular and Extracellular Mediators | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,176,373 | February 1, 2019 | June 30, 2027 | SPIEGELMAN, BRUCE M. | reporter.nih.gov |
| Targeting Pediatric Cancer Vulnerabilities | NIH | National Cancer Institute | 2023 to 2025 | $3,144,539 | September 19, 2023 | August 31, 2030 | STEGMAIER, KIMBERLY | reporter.nih.gov |
| Genetic Predisposition to Chronic Lymphocytic Leukemia (CLL) | NIH | National Cancer Institute | 2021 to 2025 | $3,143,480 | April 1, 2021 | March 31, 2027 | BROWN, JENNIFER R | reporter.nih.gov |
| PROTECT (Harnessing PROTEin degradation for Advanced Childhood Tumors) | NIH | National Cancer Institute | 2024 to 2025 | $3,108,431 | May 1, 2024 | April 30, 2026 | STEGMAIER, KIMBERLY | reporter.nih.gov |
| Role of Phosphoinositides and Protein Kinases in the control of Cancer Metabolism | NIH | National Cancer Institute | 2022 to 2025 | $3,108,133 | September 5, 2016 | July 31, 2031 | CANTLEY, LEWIS C. | reporter.nih.gov |
| Personal tumor neoantigens for immunity against chronic lymphocytic leukemia | NIH | National Cancer Institute | 2022 to 2025 | $2,996,021 | June 1, 2011 | January 31, 2027 | WU, CATHERINE JU-YING | reporter.nih.gov |
| Systematic identification of minor histocompatibility antigens to address GVHD | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,991,041 | April 1, 2022 | March 31, 2026 | KESKIN, DERIN B | reporter.nih.gov |
| Molecular mechanisms underlying lineage plasticity in prostate cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,937,823 | April 1, 2025 | March 31, 2027 | BELTRAN, HIMISHA | reporter.nih.gov |
| Tissue-based biomarkers of anti-PD-1-based therapy in metastatic renal cell carcinoma | NIH | National Cancer Institute | 2022 to 2025 | $2,841,134 | July 1, 2022 | June 30, 2027 | CHOUEIRI, TONI | reporter.nih.gov |
| Next Generation Computational Tools for Functional Genomics | NIH | National Human Genome Research Institute | 2021 to 2024 | $2,808,837 | September 22, 2020 | June 30, 2026 | IRIZARRY, RAFAEL ANGEL | reporter.nih.gov |
| Adapting and evaluating a brief advice tobacco intervention in high-reach, low-resource settings in India | NIH | National Cancer Institute | 2021 to 2024 | $2,800,655 | June 1, 2020 | May 31, 2026 | VISWANATH, KASISOMAYAJULA | reporter.nih.gov |
| Defining mechanisms of extracellular succinate regulation over metabolic tissue function | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,748,905 | September 13, 2019 | June 30, 2028 | CHOUCHANI, EDWARD THOMAS | reporter.nih.gov |
| Development of microRNA (miR)-based cell-targeted polymeric nanoparticles for myeloma therapy | NIH | National Cancer Institute | 2021 to 2025 | $2,723,368 | February 9, 2021 | March 31, 2027 | CARRASCO, RUBEN D | reporter.nih.gov |
| Generating a full-length reference transcriptome for human protein-coding genes | NIH | National Human Genome Research Institute | 2022 to 2025 | $2,708,609 | August 22, 2022 | June 30, 2027 | VIDAL, MARC | reporter.nih.gov |
| Probing the role of somatic X-chromosome alterations in shaping cancer sex differences | NIH | National Cancer Institute | 2023 to 2025 | $2,705,278 | September 20, 2023 | August 31, 2028 | VISWANATHAN, SRINIVAS RAGHAVAN | reporter.nih.gov |
| A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies | NIH | National Cancer Institute | 2022 to 2025 | $2,688,808 | March 1, 2022 | February 28, 2027 | REINHERZ, ELLIS L | reporter.nih.gov |
| Selective disruption of histone deacetylase complexes using protein interaction modulators | NIH | National Cancer Institute | 2022 to 2025 | $2,674,355 | February 1, 2022 | January 31, 2027 | VIDAL, MARC | reporter.nih.gov |
| How the 3D Architecture of the Brain Shapes Cancer Cell Fate Decisions | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $2,670,000 | September 30, 2021 | August 31, 2026 | FILBIN, MARIELLA GRUBER | reporter.nih.gov |
| Serologic and Molecular Studies of human anti-hCoV antibody cross-immunity and protective responses among endemic HCoVs and SARS-CoV2 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,655,001 | September 17, 2021 | August 31, 2025 | MARASCO, WAYNE A. | reporter.nih.gov |
| Promoting Resilience in Early Survivorship among Adolescents and Young Adults with Cancer | NIH | National Cancer Institute | 2023 to 2025 | $2,642,459 | March 10, 2022 | February 28, 2027 | ROSENBERG, ABBY R | reporter.nih.gov |
| Synthetic lethalities to cell cycle disruption in glioma | NIH | National Cancer Institute | 2022 to 2025 | $2,642,252 | May 13, 2022 | April 30, 2027 | BEROUKHIM, RAMEEN | reporter.nih.gov |
| Probing functional HIV-1 envelope glycoprotein conformations with novel potent CD4-mimetic compounds | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,540,958 | July 10, 2023 | June 30, 2027 | SODROSKI, JOSEPH G | reporter.nih.gov |
| Therapeutic Targeting of Immune Evasion from the MICA - NKG2D Pathway | NIH | National Cancer Institute | 2021 to 2025 | $2,508,450 | March 1, 2019 | March 31, 2030 | WUCHERPFENNIG, KAI W | reporter.nih.gov |
| Discovery of cGAS-like signaling enzymes in innate immunity and disease | NIH | National Institute of General Medical Sciences | 2021 to 2024 | $2,498,400 | September 24, 2021 | August 31, 2026 | KRANZUSCH, PHILIP J | reporter.nih.gov |
| Targeting SHP-1 through a newfound metabolite-regulated cysteine activation site | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,496,633 | September 25, 2023 | July 31, 2028 | CHOUCHANI, EDWARD THOMAS | reporter.nih.gov |
| Leveraging Novel Randomized Clinical Trials of Vitamin D Supplementation in Patients with Colorectal Cancer: Impact on Survival and Anti-Tumor Immunity | NIH | National Cancer Institute | 2021 to 2025 | $2,477,583 | March 15, 2017 | June 30, 2027 | NG, KIMMIE | reporter.nih.gov |
| Mouse models of Kras-mutant colorectal cancer | NIH | National Cancer Institute | 2021 to 2024 | $2,463,211 | July 1, 2020 | June 30, 2026 | HAIGIS, KEVIN | reporter.nih.gov |
| Convergent Epigenetic Control of Neuroendocrine Cancers | NIH | National Cancer Institute | 2025 | $2,452,400 | April 1, 2025 | March 31, 2030 | DECAPRIO, JAMES A. | reporter.nih.gov |
| Data Analysis Tools for Emerging High-throughput Technologies | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,410,347 | May 1, 2019 | May 31, 2030 | IRIZARRY, RAFAEL ANGEL | reporter.nih.gov |
| Discovery and optimization of novel mutant-selective allosteric inhibitors of EGFR T790M | NIH | National Cancer Institute | 2021 to 2025 | $2,408,596 | December 1, 2015 | November 30, 2025 | ECK, MICHAEL J | reporter.nih.gov |
| Liquid biopsy approaches to inform osteosarcoma prognosis and tumor evolution | NIH | National Cancer Institute | 2021 to 2025 | $2,405,560 | July 1, 2025 | June 30, 2027 | CROMPTON, BRIAN | reporter.nih.gov |
| The construction and utility of reference pan-genome graphs | NIH | National Human Genome Research Institute | 2021 to 2023 | $2,401,989 | February 4, 2023 | February 29, 2024 | LI, HENG | reporter.nih.gov |
| Translation of a Bismuth-Gadolinium Nanoparticle for MR-guided Radiation Therapy | NIH | National Cancer Institute | 2021 to 2024 | $2,352,523 | March 1, 2020 | February 28, 2026 | BERBECO, ROSS I. | reporter.nih.gov |
| Physician Scientist Training in Cancer Research | NIH | National Cancer Institute | 2021 to 2025 | $2,326,588 | July 1, 1978 | June 30, 2027 | DECAPRIO, JAMES A. | reporter.nih.gov |
| A novel flat-panel detector for advanced on-board radiation therapy imaging | NIH | National Cancer Institute | 2021 to 2024 | $2,324,892 | September 1, 2014 | June 30, 2025 | BERBECO, ROSS I. | reporter.nih.gov |
| Axonal transport and chemotherapy induced peripheral neuropathy | NIH | National Cancer Institute | 2022 to 2025 | $2,319,802 | April 1, 2016 | June 30, 2027 | SEGAL, ROSALIND A. | reporter.nih.gov |
| Immunotherapeutic targeting of gangliosides in Ewing Sarcoma | NIH | National Cancer Institute | 2023 to 2025 | $2,317,710 | September 19, 2023 | August 31, 2028 | MAJZNER, ROBBIE G. | reporter.nih.gov |
| Defining the landscape and mechanisms of protein redox regulation during aging | NIH | National Institute on Aging | 2022 to 2025 | $2,304,037 | September 15, 2022 | June 30, 2027 | CHOUCHANI, EDWARD THOMAS | reporter.nih.gov |
| Tracing the lineage histories and differentiation trajectories of individual cancer cells in myeloproliferative neoplasms | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,295,485 | January 15, 2021 | January 31, 2026 | HORMOZ, SAHAND | reporter.nih.gov |
| Mechanisms of eIF3-mediated translation regulation | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,238,573 | August 16, 2021 | July 31, 2026 | LEE, AMY SI-YING | reporter.nih.gov |
| CDK4/6 inhibition during CD8 T cell priming potentiates memory formation in mice and humans | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,225,000 | April 5, 2021 | March 31, 2027 | DOUGAN, STEPHANIE | reporter.nih.gov |
| Consequences of retrotransposition on genome integrity | NIH | National Cancer Institute | 2023 to 2025 | $2,208,749 | August 1, 2023 | July 31, 2028 | BURNS, KATHLEEN H | reporter.nih.gov |
| Molecular Pathogenesis of Fanconi Anemia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,183,099 | August 1, 1994 | December 31, 2027 | D'ANDREA, ALAN D. | reporter.nih.gov |
| Mitoribosome protein translation signaling and survival mechanisms | NIH | National Institute on Aging | 2023 to 2025 | $2,167,472 | September 30, 2023 | May 31, 2028 | PUIGSERVER, PERE | reporter.nih.gov |
| SPORE in Myeloid Malignancies | NIH | National Cancer Institute | 2021 | $2,138,999 | September 19, 2017 | July 31, 2023 | EBERT, BENJAMIN LEVINE | reporter.nih.gov |
| Targeting Nucleotide Excision Repair Deficiency to Improve Bladder Sparing Treatment for Muscle Invasive Bladder Cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,132,323 | September 22, 2022 | August 31, 2027 | MOUW, KENT W | reporter.nih.gov |
| Mechanisms of Toxicity Induced by EWS/FLI1 Overdose in Ewing Sarcoma | NIH | National Cancer Institute | 2023 to 2025 | $2,124,600 | June 7, 2023 | May 31, 2028 | STEGMAIER, KIMBERLY | reporter.nih.gov |
| Developing Informatics Technologies to Model Cancer Gene Regulation | NIH | National Cancer Institute | 2021 to 2023 | $2,108,794 | March 15, 2019 | February 29, 2024 | MEYER, CLIFFORD | reporter.nih.gov |
| BOLSTER: Strengthening Patient and Caregiver Supports in Advanced Gynecologic and Gastrointestinal Cancers - a Multi-Site Randomized Controlled Trial | NIH | National Cancer Institute | 2023 to 2025 | $2,088,479 | February 1, 2023 | July 31, 2028 | WRIGHT, ALEXI A | reporter.nih.gov |
| Development and vascularity of intestinal mesenchyme | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,083,022 | June 1, 2019 | April 30, 2028 | SHIVDASANI, RAMESH A | reporter.nih.gov |
| Mechanisms and Vulnerabilities of Aberrant Transcriptional Enhancers in Cancer | NIH | National Cancer Institute | 2021 to 2022 | $2,071,954 | September 1, 2016 | August 31, 2023 | LOOK, A. THOMAS | reporter.nih.gov |
| Integrating Transforming Approaches to Identify and Target New Vulnerabilities in Cancer | NIH | National Cancer Institute | 2021 to 2022 | $2,071,953 | August 9, 2016 | July 31, 2023 | STEGMAIER, KIMBERLY | reporter.nih.gov |
| Cyclin C-CDK8/19 kinases in development and in cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,067,060 | March 1, 2022 | February 28, 2027 | SICINSKI, PETER | reporter.nih.gov |
| Advanced computational methods in analyzing high-throughput sequencing data | NIH | National Human Genome Research Institute | 2021 to 2025 | $2,058,625 | May 1, 2018 | February 28, 2027 | LI, HENG | reporter.nih.gov |
| Regulatory mechanisms of mitochondrial cristae biogenesis and thermogenic function | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $2,047,746 | August 1, 2023 | July 31, 2027 | PUIGSERVER, PERE | reporter.nih.gov |
| Developing non-immunosuppressive immune-based therapeutics for targeted treatment of autoimmune diseases | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,028,057 | August 24, 2023 | July 31, 2028 | RASHIDIAN, MOHAMMAD | reporter.nih.gov |
| Mechanisms Driving the Rapid Evolution of Cancer Genomes | NIH | National Cancer Institute | 2024 to 2025 | $2,010,442 | September 1, 2024 | August 31, 2031 | PELLMAN, DAVID S | reporter.nih.gov |
| Optimizing Therapeutic STING Agonism in Triple Negative Breast Cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,007,374 | April 1, 2021 | March 31, 2027 | BARBIE, THANH UYEN | reporter.nih.gov |
| Molecular origins and evolution to chemoresistance in germ cell tumors | NIH | National Cancer Institute | 2021 to 2024 | $2,002,931 | February 1, 2023 | January 31, 2025 | VAN ALLEN, ELIEZER M | reporter.nih.gov |
| Targeting vulnerabilities of PPM1D-mutant gliomas | NIH | National Cancer Institute | 2021 to 2025 | $1,989,782 | February 1, 2021 | January 31, 2026 | BANDOPADHAYAY, PRATITI | reporter.nih.gov |
| Defining epigenetic mechanisms in NPM1c mutant leukemia | NIH | National Cancer Institute | 2021 to 2025 | $1,981,710 | April 9, 2021 | March 31, 2027 | ARMSTRONG, SCOTT A | reporter.nih.gov |
| Novobiocin-mediated polymerase theta inhibition in homologous recombination repair-deficient cancers | NIH | National Cancer Institute | 2022 to 2025 | $1,976,994 | September 1, 2022 | August 31, 2027 | SHAPIRO, GEOFFREY I. | reporter.nih.gov |
| The molecular basis of IMiD induced neo-substrate recruitment to the CRL4CRBN ubiquitin E3 ligase | NIH | National Cancer Institute | 2021 to 2025 | $1,973,693 | March 1, 2017 | March 31, 2027 | FISCHER, ERIC SEBASTIAN | reporter.nih.gov |
| Bioethics research to understand engagement in decision-making among adolescents and young adults with cancer at risk for health care disparities | NIH | National Cancer Institute | 2023 to 2025 | $1,967,607 | September 1, 2025 | August 31, 2026 | MACK, JENNIFER W | reporter.nih.gov |
| Training in Oncology Population Sciences (TOPS) | NIH | National Cancer Institute | 2021 to 2025 | $1,967,226 | September 1, 2002 | August 31, 2029 | MACK, JENNIFER W | reporter.nih.gov |
| Small molecules targeting hepatic glucose production and insulin resistance | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,962,658 | March 21, 2019 | February 28, 2025 | PUIGSERVER, PERE | reporter.nih.gov |
| End-of-life care quality for adolescents and young adults with cancer: Including the patient voice in quality assessment | NIH | National Cancer Institute | 2021 to 2025 | $1,960,563 | February 13, 2018 | December 31, 2029 | MACK, JENNIFER W | reporter.nih.gov |
| Polyploidy, Aneuploidy and Genome Stability | NIH | National Cancer Institute | 2021 to 2024 | $1,959,860 | May 30, 1997 | November 30, 2024 | PELLMAN, DAVID S | reporter.nih.gov |
| Development and implementation of multiplex methods to understand the biology and heterogeneity of patient-derived cancer models | NIH | National Cancer Institute | 2021 to 2022 | $1,926,843 | June 15, 2020 | May 31, 2023 | HAHN, WILLIAM C. | reporter.nih.gov |
| NMR Fingerprinting: Leveraging optimal control pulse design, tailored isotope labeling, and machine learning to study intractable proteins | NIH | National Institute of General Medical Sciences | 2021 to 2024 | $1,905,230 | June 1, 2020 | March 31, 2025 | ARTHANARI, HARIBABU | reporter.nih.gov |
| Targeting of a Major Immune Evasion Pathway in Triple-negative Breast Cancer | NIH | National Cancer Institute | 2021 to 2024 | $1,897,891 | August 1, 2020 | April 30, 2026 | WUCHERPFENNIG, KAI W | reporter.nih.gov |
| Dissecting neoepitope-specific clonal T cell populations in advanced melanoma patients vaccinated with personal neoantigen peptides partnered with local and systemic immune checkpoint Inhibition | NIH | National Cancer Institute | 2021 to 2023 | $1,871,288 | September 6, 2018 | August 31, 2025 | OTT, PATRICK ALEXANDER | reporter.nih.gov |
| Research Training in Pediatric Oncology | NIH | National Cancer Institute | 2021 to 2024 | $1,864,901 | July 13, 2009 | June 30, 2025 | ARMSTRONG, SCOTT A | reporter.nih.gov |
| Protein Kinase Therapeutic Targets for Non-Small Cell Lung Carcinoma | NIH | National Cancer Institute | 2021 | $1,846,173 | May 11, 2012 | August 31, 2023 | MEYERSON, MATTHEW L. | reporter.nih.gov |
| Taking AIM at Breast Cancer: Targeting Adiposity and Inflammation with Movement to Improve Prognosis in Breast Cancer Survivors | NIH | National Cancer Institute | 2021 to 2023 | $1,845,213 | September 1, 2018 | August 31, 2025 | DIELI-CONWRIGHT, CHRISTINA | reporter.nih.gov |
| Development of a generalizable chemo-proteomics screening platform for small molecule degraders applied to HDACs | NIH | National Cancer Institute | 2022 to 2025 | $1,822,992 | June 7, 2022 | April 30, 2026 | FISCHER, ERIC SEBASTIAN | reporter.nih.gov |
| CDC7 kinase in normal and cancer cells: potential implications for cancer treatment | NIH | National Cancer Institute | 2021 to 2024 | $1,822,777 | December 1, 2019 | November 30, 2024 | SICINSKI, PETER | reporter.nih.gov |
| Statistical methods for cancer mutational signatures | NIH | National Cancer Institute | 2021 to 2025 | $1,815,915 | July 1, 2021 | June 30, 2026 | PARMIGIANI, GIOVANNI LUIGI | reporter.nih.gov |
| Engineering dendritic cells to target islet antigen to pro-tolerogenic subsets for prevention and treatment of Type 1 Diabetes | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $1,780,000 | April 1, 2022 | March 31, 2027 | AGUDO CANTERO, JUDITH | reporter.nih.gov |
| Individualizing Approaches to Surveillance Mammography in Older Breast Cancer Survivors | NIH | National Institute on Aging | 2024 to 2025 | $1,777,442 | September 15, 2024 | August 31, 2030 | FREEDMAN, RACHEL ANN | reporter.nih.gov |
| Dissecting the interaction between DNA damage repair defects and the tumor microenvironment | NIH | Office of the Director, National Institutes of Health | 2021 to 2024 | $1,770,000 | September 16, 2020 | August 31, 2025 | HILL, SARAH JAMES | reporter.nih.gov |
| Targeting blastic plasmacytoid dendritic cell neoplasm (BPDCN) | NIH | National Cancer Institute | 2021 to 2024 | $1,737,621 | February 1, 2018 | January 31, 2026 | LANE, ANDREW A | reporter.nih.gov |
| Rewiring of regulatory networks in breast cancer by transcription factor isoforms | NIH | National Cancer Institute | 2021 to 2022 | $1,735,449 | September 17, 2018 | February 29, 2024 | VIDAL, MARC | reporter.nih.gov |
| Enhancement and further development of informatics methods for long-read cancer sequencing | NIH | National Cancer Institute | 2024 to 2025 | $1,730,589 | September 1, 2024 | August 31, 2029 | LI, HENG | reporter.nih.gov |
| Targeting the MUC1-C Oncoprotein in Triple-Negative Breast Cancer | NIH | National Cancer Institute | 2021 to 2025 | $1,714,463 | July 1, 2002 | March 31, 2029 | KUFE, DONALD W. | reporter.nih.gov |
| Investigating and modeling MYD88L265P and co-occurring mutations in mature B-cell malignancies | NIH | National Cancer Institute | 2022 to 2025 | $1,713,034 | August 1, 2022 | July 31, 2027 | CARRASCO, RUBEN D | reporter.nih.gov |
| Early change in plasma tumor DNA as a patient and trial-level diagnostic in advanced lung cancer | NIH | National Cancer Institute | 2021 to 2024 | $1,712,649 | February 15, 2020 | January 31, 2025 | PAWELETZ, CLOUD PETER | reporter.nih.gov |
| Yoga for Chemotherapy-induced Peripheral Neuropathy Treatment (YCT) Trial | NIH | National Cancer Institute | 2023 to 2025 | $1,709,232 | April 1, 2021 | September 30, 2026 | BAO, TING | reporter.nih.gov |
| NexTGen - DFCI | NIH | National Cancer Institute | 2023 to 2025 | $1,705,825 | June 1, 2025 | May 31, 2026 | MAJZNER, ROBBIE G. | reporter.nih.gov |
| Molecular and immune drivers of immunotherapy responsiveness in prostate cancer | NIH | National Cancer Institute | 2021 to 2022 | $1,689,999 | September 19, 2018 | August 31, 2023 | VAN ALLEN, ELIEZER M | reporter.nih.gov |
| Hijacking the T cell machinery for logic-gated CAR T cell control | NIH | National Cancer Institute | 2021 to 2024 | $1,684,559 | September 24, 2021 | August 31, 2026 | MAJZNER, ROBBIE G. | reporter.nih.gov |
| Stapled Peptides for Protein Interaction Research and Therapeutic Targeting in Human Cancer | NIH | National Cancer Institute | 2021 to 2025 | $1,660,410 | September 15, 2016 | August 31, 2026 | BIRD, GREGORY HOWARD | reporter.nih.gov |
| MUC1-C is a Target for Reversing Immune Evasion and Resistance to Immunotherapies | NIH | National Cancer Institute | 2021 to 2022 | $1,659,300 | September 20, 2018 | August 31, 2024 | KUFE, DONALD W. | reporter.nih.gov |
| Mechanisms of response and resistance to KRAS inhibition in pancreatic cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,657,228 | January 1, 2023 | December 31, 2027 | AGUIRRE, ANDREW JAMES | reporter.nih.gov |
| High-throughput single-cell RNA sequencing of bacteria to uncover cell states involved in pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,646,044 | June 20, 2024 | April 30, 2029 | HORMOZ, SAHAND | reporter.nih.gov |
| Identification of Novel Protein Kinases Dependent on Phosphocreatine Rather than ATP | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $1,641,114 | August 31, 2018 | July 31, 2024 | SPIEGELMAN, BRUCE M. | reporter.nih.gov |
| Enhanced radiotherapy for pediatric glioma via synthetic lethal vulnerabilities | NIH | National Cancer Institute | 2024 to 2025 | $1,637,935 | July 1, 2024 | June 30, 2026 | CHOWDHURY, DIPANJAN | reporter.nih.gov |
| Targeting the cytokine circuitry of KRAS-driven lung cancer | NIH | National Cancer Institute | 2021 to 2024 | $1,625,555 | April 1, 2015 | May 31, 2026 | BARBIE, DAVID A | reporter.nih.gov |
| Human Cancer Suppressor Functions of Protein Phosphatase 2A | NIH | National Cancer Institute | 2021 | $1,613,905 | August 1, 2017 | July 31, 2023 | DECAPRIO, JAMES A. | reporter.nih.gov |
| A web-based patient-reported symptom monitoring and self-management portal for adolescent and young adult breast cancer survivors | NIH | National Cancer Institute | 2023 to 2024 | $1,613,871 | September 18, 2020 | August 31, 2025 | PARTRIDGE, ANN H | reporter.nih.gov |
| Optimizing novel agent combination therapy for previously untreated, high risk chronic lymphocytic leukemia | NIH | National Cancer Institute | 2022 to 2025 | $1,603,351 | September 15, 2022 | June 30, 2027 | DAVIDS, MATTHEW S | reporter.nih.gov |
| Engineering programmable enzymes for proteome editing | NIH | National Institute of General Medical Sciences | 2023 | $1,602,000 | September 1, 2023 | August 31, 2026 | ZHOU, XIN | reporter.nih.gov |
| Computational methods for multiplex image analysis of the tumor microenvironment | NIH | National Library of Medicine | 2025 | $1,602,000 | September 1, 2025 | August 31, 2029 | LOTTER, WILLIAM EDWARD | reporter.nih.gov |
| Cellular and Biochemical Pathways of Adipose Metabolism and Thermogenesis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,596,762 | December 10, 2019 | November 30, 2024 | SPIEGELMAN, BRUCE M. | reporter.nih.gov |
| Cell lineage as an indicator of immune response in neuroblastoma | NIH | National Cancer Institute | 2022 to 2025 | $1,593,136 | June 16, 2022 | May 31, 2027 | GEORGE, RANI E. | reporter.nih.gov |
| Characterizing the LINE-1 Retrotransposition-Replication Conflict | NIH | National Cancer Institute | 2021 to 2024 | $1,583,112 | July 15, 2020 | June 30, 2025 | BURNS, KATHLEEN H | reporter.nih.gov |
| Metabolic and epigenetic dependencies in melanomas during metastasis and targeted-drug resistance | NIH | National Cancer Institute | 2021 to 2024 | $1,582,220 | July 1, 2014 | March 31, 2026 | PUIGSERVER, PERE | reporter.nih.gov |
| Targeting of tumor cell DHHC3 to enhance anti-cancer immunity | NIH | National Cancer Institute | 2021 to 2024 | $1,564,826 | March 1, 2020 | February 28, 2025 | HEMLER, MARTIN E | reporter.nih.gov |
| Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV) | NIH | National Cancer Institute | 2021 to 2023 | $1,553,684 | July 10, 2023 | August 31, 2024 | GRAY, ROBERT J | reporter.nih.gov |
| Elucidating the molecular mechanism and physiological relevance of TIRR mediated inhibition of p53 | NIH | National Cancer Institute | 2022 to 2025 | $1,529,566 | July 1, 2022 | June 30, 2027 | CHOWDHURY, DIPANJAN | reporter.nih.gov |
| Statistical Methods and Validation Analyses for the Integration of External Data in Clinical Trials | NIH | National Library of Medicine | 2021 to 2024 | $1,524,272 | April 7, 2021 | December 31, 2025 | TRIPPA, LORENZO | reporter.nih.gov |
| Molecular mechanisms and therapeutic targeting of activated NRF2 signaling in MiT/TFE translocation renal cell carcinoma | NIH | National Cancer Institute | 2023 to 2025 | $1,516,110 | August 1, 2023 | July 31, 2028 | VISWANATHAN, SRINIVAS RAGHAVAN | reporter.nih.gov |
| Variability in Opioid Prescribing Across the Cancer Care Continuum: A Multi-Level Analysis | NIH | National Cancer Institute | 2024 to 2025 | $1,501,571 | February 21, 2024 | January 31, 2029 | ENZINGER, ANDREA C | reporter.nih.gov |
| Metabolic crosstalks in regulation of beta-cell stress response and adaptation | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,469,732 | February 1, 2008 | March 31, 2027 | DANIAL, NIKA N | reporter.nih.gov |
| Dissecting Integrated Cellular Programs Promoting Platinum Resistance and Progression in Bladder Cancer | NIH | National Cancer Institute | 2024 to 2025 | $1,461,918 | April 1, 2024 | March 31, 2029 | VAN ALLEN, ELIEZER M | reporter.nih.gov |
| Design of a Scalable and Sustainable PREMMplus Patient-Facing App and Implementation in Three Healthcare Settings | NIH | National Cancer Institute | 2024 to 2025 | $1,455,977 | September 4, 2024 | August 31, 2029 | SYNGAL, SAPNA | reporter.nih.gov |
| The role of NCOA4-mediated ferritinophagy in iron homeostasis and ferroptosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,455,601 | April 1, 2020 | March 31, 2026 | MANCIAS, JOSEPH D | reporter.nih.gov |
| Novel Health Equity Intervention to Improve Pediatric Oncology Outcome Disparities: Targeting Poverty and Psychosocial Stress | NIH | National Cancer Institute | 2022 to 2023 | $1,449,123 | March 1, 2022 | February 29, 2028 | BONA, KIRA O. | reporter.nih.gov |
| Transcriptional control and enhancer recruitment in mouse and human intestinal secretory differentiation | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $1,447,944 | September 1, 2010 | February 29, 2028 | SHIVDASANI, RAMESH A | reporter.nih.gov |
| Merkel cell polyomavirus HLA class I epitopes for generating therapeutic T cell-based cancer immunotherapy | NIH | National Cancer Institute | 2024 to 2025 | $1,438,870 | January 9, 2024 | December 31, 2028 | KESKIN, DERIN B | reporter.nih.gov |
| Randomized trial of REVITALIZE: A telehealth intervention to reduce fatigue interference among adults with advanced ovarian cancer on PARP inhibitors | NIH | National Cancer Institute | 2024 to 2025 | $1,433,938 | June 1, 2024 | May 31, 2029 | WRIGHT, ALEXI A | reporter.nih.gov |
| Mechanism and functional consequences of dietary lipids in lineage specification and tumor growth in oncohistone gliomas | NIH | National Cancer Institute | 2024 to 2025 | $1,424,418 | April 1, 2024 | March 31, 2029 | DANIAL, NIKA N | reporter.nih.gov |
| Dissecting Convergent Somatic and Germline Alterations that Mediate the Origins and Evolution of Kidney Cancer | NIH | National Cancer Institute | 2024 to 2025 | $1,419,944 | January 1, 2024 | December 31, 2028 | VAN ALLEN, ELIEZER M | reporter.nih.gov |
| Novel therapeutic approaches with CDK4/6 inhibitors for melanoma treatment | NIH | National Cancer Institute | 2021 to 2023 | $1,413,825 | December 1, 2018 | November 30, 2024 | SICINSKI, PETER | reporter.nih.gov |
| (PQ3) A functional genomic approach to identification and interpretation of germline-tumor genetic interactions | NIH | National Cancer Institute | 2021 to 2022 | $1,400,066 | June 8, 2018 | May 31, 2024 | GUSEV, ALEXANDER | reporter.nih.gov |
| BIDIRECTIONAL TRAINING TO ENHANCE CANCER RESEARCH CAPACITY IN AFRICA | NIH | National Cancer Institute | 2021 to 2025 | $1,388,758 | May 5, 2021 | April 30, 2027 | REBBECK, TIMOTHY RICHARD | reporter.nih.gov |
| HEME-Hospice: An Intervention to improve Hospice Use for Patients with Hematologic Malignancies | NIH | National Cancer Institute | 2024 to 2025 | $1,375,196 | June 1, 2024 | May 31, 2029 | MACK, JENNIFER W | reporter.nih.gov |
| Tissue-specific genetic interactions in cancer | NIH | National Cancer Institute | 2021 to 2022 | $1,375,018 | June 20, 2018 | May 31, 2024 | HAIGIS, KEVIN | reporter.nih.gov |
| Mechanisms by which LSD1 Promotes Neuroendocrine Differentiation and Small Cell Lung Cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,367,119 | December 6, 2022 | November 30, 2027 | OSER, MATTHEW GILBERT | reporter.nih.gov |
| Assessment of germline variants associated with immune-related adverse events following immune checkpoint inhibitors | NIH | National Cancer Institute | 2024 to 2025 | $1,357,987 | September 17, 2024 | August 31, 2029 | CHOUEIRI, TONI | reporter.nih.gov |
| Mechanisms of immune evasion in T-cell acute lymphoblastic leukemia and its therapeutic implications | NIH | National Cancer Institute | 2021 to 2024 | $1,355,619 | August 24, 2021 | August 31, 2024 | KNOECHEL, BIRGIT | reporter.nih.gov |
| Interface-resolution domain-domain interactome map of the yeast complexome | NIH | National Institute of General Medical Sciences | 2021 to 2022 | $1,340,062 | April 20, 2019 | February 29, 2024 | VIDAL, MARC | reporter.nih.gov |
| Molecular origins and evolution to treatment resistance in genitourinary cancers | NIH | National Cancer Institute | 2022 to 2025 | $1,321,652 | August 1, 2022 | July 31, 2027 | PARK, JIHYE | reporter.nih.gov |
| The Function of CDK5 in Metastasis | NIH | National Cancer Institute | 2021 to 2023 | $1,306,325 | March 1, 2019 | February 28, 2025 | SICINSKI, PETER | reporter.nih.gov |
| Scaling up tobacco control in India: Comparing smartphone to in-person training for implementing an evidence-based intervention to reduce tobacco use among schoolteachers | NIH | National Cancer Institute | 2021 to 2024 | $1,305,092 | September 1, 2021 | July 31, 2025 | NAGLER, EVE M | reporter.nih.gov |
| Effects of marijuana use on inflammation and vascular injury in adults with HIV infection | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,297,182 | April 1, 2018 | February 28, 2025 | GABUZDA, DANA H. | reporter.nih.gov |
| Acupuncture for Chemothrapy-induced Peripheral Neuropathy Treatment (ACT) Trial | NIH | National Cancer Institute | 2024 to 2025 | $1,263,296 | December 1, 2023 | November 30, 2025 | BAO, TING | reporter.nih.gov |
| Anatomic and functional characterization of the intestinal crypt-villus niche | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,258,950 | September 1, 2014 | August 31, 2024 | SHIVDASANI, RAMESH A | reporter.nih.gov |
| Can a subset of patients with HER2+ metastatic breast cancer be cured? | NIH | National Cancer Institute | 2021 to 2025 | $1,229,054 | April 1, 2021 | July 1, 2025 | PARSONS, HEATHER ANNE | reporter.nih.gov |
| Cancer-Specific Targeting and Function of Mammalian SWI/SNF (BAF) Chromatin Remodeling Complexes | NIH | National Cancer Institute | 2021 to 2023 | $1,227,497 | March 21, 2019 | February 29, 2024 | KADOCH, CIGALL | reporter.nih.gov |
| Regulators of Cancer Immunotherapy Response | NIH | National Cancer Institute | 2021 to 2022 | $1,203,365 | May 15, 2019 | April 30, 2024 | BROWN, MYLES A | reporter.nih.gov |
| Novel Screening Platform for Discovery of DUB Targeting Probes | NIH | National Cancer Institute | 2021 to 2022 | $1,202,534 | June 1, 2019 | May 31, 2024 | BUHRLAGE, SARA J | reporter.nih.gov |
| Mechanisms of natural killer cell resistance of treatment-persistent residual tumor cells in hematologic malignancies | NIH | National Cancer Institute | 2023 to 2025 | $1,194,750 | January 1, 2023 | December 31, 2027 | MITSIADES, CONSTANTINE S. | reporter.nih.gov |
| Incomplete Penetrance via Edgetic Suppression | NIH | National Institute of General Medical Sciences | 2021 to 2022 | $1,182,382 | September 10, 2019 | August 31, 2024 | VIDAL, MARC | reporter.nih.gov |
| Cancer Chemical Biology and Metabolism Training Program | NIH | National Cancer Institute | 2021 to 2023 | $1,167,548 | April 1, 2019 | March 31, 2025 | DANIAL, NIKA N | reporter.nih.gov |
| Regulation and targeting of tumor cell states and plasticity in pancreatic cancer | NIH | National Cancer Institute | 2022 to 2025 | $1,164,735 | September 1, 2022 | August 31, 2027 | RAGHAVAN, SRIVATSAN | reporter.nih.gov |
| Immunotherapeutic responses to neoantigens in head and neck cancer | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2022 | $1,150,293 | April 11, 2018 | March 31, 2024 | UPPALURI, RAVINDRA | reporter.nih.gov |
| BMT CTN Core - Dana-Farber Cancer Institute and MGH Consortium | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $1,133,713 | September 30, 2001 | June 30, 2031 | GOOPTU, MAHASWETA | reporter.nih.gov |
| CDK7 inhibitors as a new strategy to overcome treatment resistance in ER+ metastatic breast cancer | NIH | National Cancer Institute | 2021 to 2023 | $1,125,683 | August 16, 2019 | July 31, 2025 | JESELSOHN, RINATH M. | reporter.nih.gov |
| (PQ5) Contribution of mitochondrial pathways to metabolic heterogeneity in molecular subtypes of Diffuse Large B Cell Lymphoma | NIH | National Cancer Institute | 2021 to 2022 | $1,104,883 | September 1, 2018 | February 29, 2024 | DANIAL, NIKA N | reporter.nih.gov |
| Molecular mechanisms of developmental reprogramming in colorectal cancer | NIH | National Cancer Institute | 2024 to 2025 | $1,103,696 | September 1, 2024 | August 31, 2029 | SETHI, NILAY | reporter.nih.gov |
| Comprehensive genomic profiling of aggressive hormone sensitive prostate cancer | NIH | National Cancer Institute | 2021 to 2022 | $1,091,437 | May 1, 2020 | April 30, 2023 | SWEENEY, CHRISTOPHER J | reporter.nih.gov |
| Novel targeted therapies for chronic myelomonocytic leukemia | NIH | National Cancer Institute | 2022 to 2025 | $1,076,976 | September 2, 2022 | August 31, 2027 | BELIZAIRE, ROGER VINCENT | reporter.nih.gov |
| Regulation of androgen receptor signaling in prostate cancer by protein arginine methylation | NIH | National Cancer Institute | 2023 to 2024 | $1,076,279 | April 1, 2023 | March 31, 2028 | VISWANATHAN, SRINIVAS RAGHAVAN | reporter.nih.gov |
| Assay Validation of a Circulating miRNA Test for Diagnosis and Monitoring of Malignant Germ Cell Tumors | NIH | National Cancer Institute | 2022 to 2024 | $1,075,002 | September 2, 2019 | April 30, 2025 | FRAZIER, ANNE LINDSAY | reporter.nih.gov |
| EZH2 in cancer biology and novel inhibitors | NIH | National Cancer Institute | 2021 to 2022 | $1,065,357 | August 1, 2018 | July 31, 2023 | QI, JUN | reporter.nih.gov |
| Deciphering the mechanism underlying BRCA1 breast cancer development | NIH | National Cancer Institute | 2021 | $1,053,423 | August 7, 2019 | February 28, 2023 | LIVINGSTON, DAVID MORSE | reporter.nih.gov |
| Cell Cycle Control of the Cytoskeleton | NIH | National Institute of General Medical Sciences | 2021 to 2023 | $1,041,300 | July 1, 2000 | July 31, 2024 | PELLMAN, DAVID S | reporter.nih.gov |
| High-Throughput DNA Sequencing System | NIH | Office of the Director, National Institutes of Health | 2024 | $1,035,125 | July 15, 2024 | June 30, 2025 | HERBERT, ZACHARY T | reporter.nih.gov |
| Enhancing Venetoclax Activity in Chemoresistant Acute Myeloid Leukemia | NIH | National Cancer Institute | 2021 to 2024 | $1,034,244 | March 1, 2020 | August 31, 2025 | GARCIA, JACQUELINE SUEN | reporter.nih.gov |
| Harnessing naturally occurring cell type-specific regulatory elements and normal HSC hematopoiesis to develop cell lineage-controlled CAR expression and continuously renewing CAR NK cells | NIH | National Cancer Institute | 2024 to 2025 | $1,027,718 | August 1, 2024 | July 31, 2029 | SMITH, ERIC L | reporter.nih.gov |
| Targeting High-Risk Lymphoid Neoplasms | NIH | National Cancer Institute | 2021 | $1,021,025 | August 1, 2019 | June 30, 2022 | WEINSTOCK, DAVID MARC | reporter.nih.gov |
| Diversifying Acute Leukemia Clinical Trial Enrollment Through Multilevel Intervention | NIH | National Cancer Institute | 2022 to 2025 | $1,020,592 | July 1, 2022 | June 30, 2027 | HANTEL, ANDREW | reporter.nih.gov |
| Integrative modelling of single-cell data to elucidate the genetic architecture of complex disease | NIH | National Human Genome Research Institute | 2024 to 2025 | $1,009,988 | August 1, 2024 | April 30, 2028 | GUSEV, ALEXANDER | reporter.nih.gov |
| The Dana-Farber Cancer Institute Cancer Target Discovery and Development Center | NIH | National Cancer Institute | 2021 | $1,007,904 | May 1, 2013 | July 31, 2023 | HAHN, WILLIAM C. | reporter.nih.gov |
| Contribution of a novel OPN-producing CD11c+ microglial subset to AD | NIH | National Institute on Aging | 2024 to 2025 | $1,001,829 | February 1, 2024 | December 31, 2028 | CANTOR, HARVEY | reporter.nih.gov |
| Cancer Immunologic Data Commons (CIDC) Supplement Request | NIH | National Cancer Institute | 2022 | $1,000,000 | September 30, 2017 | June 30, 2023 | CERAMI, ETHAN | reporter.nih.gov |
| Dissecting and Targeting MAPK - PPARG Crosstalk in Bladder Cancer | NIH | National Cancer Institute | 2024 to 2025 | $985,050 | May 1, 2024 | April 30, 2029 | MOUW, KENT W | reporter.nih.gov |
| Postdoctoral Training Program in AIDS-related Research | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $978,766 | August 1, 1990 | May 31, 2025 | CANTOR, HARVEY | reporter.nih.gov |
| Tumor and host markers of clinical outcomes after MIBG therapy in neuroblastoma | NIH | National Cancer Institute | 2021 to 2023 | $942,428 | April 15, 2018 | March 31, 2025 | DUBOIS, STEVEN | reporter.nih.gov |
| Biomarker screening algorithms for the improved early detection of hepatocellular carcinoma | NIH | National Cancer Institute | 2021 to 2025 | $921,328 | April 1, 2019 | March 31, 2027 | TAYOB, NABIHAH | reporter.nih.gov |
| Investigating Transcriptional Elongation and Nuclear RNA Surveillance in Melanoma | NIH | National Cancer Institute | 2021 to 2025 | $919,990 | April 1, 2021 | March 31, 2027 | INSCO, MEGAN LEIGH | reporter.nih.gov |
| Comprehensive minimal residual disease tracking in cancer | NIH | National Cancer Institute | 2024 to 2025 | $908,380 | June 1, 2018 | November 30, 2026 | MAKRIGIORGOS, G. MIKE | reporter.nih.gov |
| Single cell investigation of co-evolution in cancer cells and host cell immune microenvironment | NIH | National Cancer Institute | 2021 to 2025 | $906,086 | August 15, 2020 | July 31, 2030 | LI, SHUQIANG | reporter.nih.gov |
| Development and validation of clinical prediction models for the use and interpretation of multigene hereditary cancer risk assessment | NIH | National Cancer Institute | 2021 to 2022 | $901,778 | September 30, 2008 | January 31, 2025 | SYNGAL, SAPNA | reporter.nih.gov |
| Genetic dissection of visceral pain pathways | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $890,366 | July 1, 2019 | September 16, 2022 | MA, QIUFU | reporter.nih.gov |
| Approaches to inducing broadly neutralizing antibodies with immunogens mimicking steric occlusion of the MPER as configured on the HIV-1virion surface | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $890,000 | August 1, 2019 | July 31, 2024 | KIM, MIKYUNG | reporter.nih.gov |
| Molecular mechanisms of splicing dependency in cohesin-mutant myelodysplasia | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $890,000 | December 1, 2023 | November 30, 2028 | TOTHOVA, ZUZANA | reporter.nih.gov |
| Elucidating the impact of DNA hypomethylation on genome organization and anti-tumor transcriptional programs | NIH | National Cancer Institute | 2021 to 2025 | $888,619 | April 1, 2021 | March 31, 2027 | JOHNSTONE, SARAH E | reporter.nih.gov |
| Defining LncRNA Function in normal and Shwachman Diamond Syndrome Myelopoiesis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $882,500 | January 15, 2019 | December 31, 2023 | NOVINA, CARL D | reporter.nih.gov |
| Functional Genomic Dissection of Refractory Anemia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $882,500 | September 15, 2005 | May 31, 2024 | EBERT, BENJAMIN LEVINE | reporter.nih.gov |
| NMR-based dynamic assessment of TCR transmembrane conformational states linked to T cell function | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $882,500 | September 24, 2018 | August 31, 2024 | REINHERZ, ELLIS L | reporter.nih.gov |
| Development, Optimization and Preclinical Modeling of Hematopoietic Stem Cell Gene Editing for the Treatment of RAG1 Immunodeficiency | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $882,201 | June 8, 2021 | June 2, 2023 | GENOVESE, PIETRO | reporter.nih.gov |
| Single Molecule Detection of L1 Insertions and Intermediates | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2024 | $878,631 | April 1, 2023 | March 31, 2025 | BURNS, KATHLEEN H | reporter.nih.gov |
| Transcriptional control of gut epithelial homeostasis and regeneration | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $878,354 | September 1, 2009 | March 31, 2024 | SHIVDASANI, RAMESH A | reporter.nih.gov |
| Elucidating the molecular and cellular mechanisms of immune evasion in pancreatic cancer | NIH | National Cancer Institute | 2022 to 2025 | $864,895 | July 1, 2022 | June 30, 2027 | FREED-PASTOR, WILLIAM A | reporter.nih.gov |
| Characterizing the XRN1 exoribonuclease as a therapeutic target in non-small cell lung cancer | NIH | National Cancer Institute | 2021 to 2025 | $861,782 | July 1, 2021 | August 1, 2025 | ZOU, TAO | reporter.nih.gov |
| New approaches to targeting cell cycle proteins for cancer treatment | NIH | National Cancer Institute | 2025 | $855,249 | September 1, 2025 | July 31, 2032 | SICINSKI, PETER | reporter.nih.gov |
| Cellular and Biochemical Pathways of Adipose Metabolism and Thermogenesis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $840,198 | July 21, 2025 | April 30, 2029 | SPIEGELMAN, BRUCE M. | reporter.nih.gov |
| ACTIVATE: AI-driven Clinical Trial Information and Viability Assessment Tool for EHRs | NIH | National Cancer Institute | 2025 | $833,467 | September 17, 2025 | August 31, 2030 | KEHL, KENNETH L | reporter.nih.gov |
| Immunologic mechanisms that prevent autoimmunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $816,829 | July 6, 2020 | January 31, 2024 | CANTOR, HARVEY | reporter.nih.gov |
| Integrative Somatic and Germline Computational Biology to Redefine Clinical Actionability in Solid Tumors | NIH | National Cancer Institute | 2021 to 2022 | $814,350 | June 1, 2018 | May 31, 2023 | VAN ALLEN, ELIEZER M | reporter.nih.gov |
| Structural Basis of Thermogenic Mitochondrial Respiratory Complexes Assembly | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $813,511 | July 21, 2025 | April 30, 2029 | PUIGSERVER, PERE | reporter.nih.gov |
| Harnessing the repetitive genome for cancer immunotherapy | NIH | National Cancer Institute | 2023 to 2025 | $806,256 | August 1, 2023 | July 31, 2028 | GRIFFIN, GABRIEL K. | reporter.nih.gov |
| Targeting DOT1L for Degradation in MLL-rearranged Leukemia | NIH | National Cancer Institute | 2021 to 2022 | $800,072 | September 25, 2012 | May 31, 2023 | ARMSTRONG, SCOTT A | reporter.nih.gov |
| Liquid biopsy in myeloma to inform outcome and treatment decisions | NIH | National Cancer Institute | 2023 to 2024 | $793,992 | January 10, 2023 | August 31, 2024 | LOHR, JENS G | reporter.nih.gov |
| The Young Empowered Scientists for ContinUed Research Engagement (YES for CURE) Program at the Dana-Farber/Harvard Cancer Center (DF/HCC) | NIH | National Cancer Institute | 2024 to 2025 | $777,512 | August 8, 2024 | July 31, 2029 | DECAPRIO, JAMES A. | reporter.nih.gov |
| Resistance and Sensitivity to MET Inhibitors in Lung Cancer | NIH | National Cancer Institute | 2021 to 2022 | $772,998 | February 1, 2018 | January 31, 2023 | JANNE, PASI A | reporter.nih.gov |
| KDM5 histone lysine demethylases as potential novel myeloid tumor suppressors | NIH | National Cancer Institute | 2021 to 2022 | $765,490 | July 1, 2018 | June 30, 2024 | LOSMAN, JULIE-AURORE | reporter.nih.gov |
| Understanding and addressing sub-optimal responses to CAR T cell therapy for Multiple Myeloma | NIH | National Cancer Institute | 2021 to 2023 | $758,211 | August 1, 2019 | July 31, 2024 | SMITH, ERIC L | reporter.nih.gov |
| Tracing the Evolution of Chronic Lymphocytic Leukemia to Richter's Syndrome: Defining Transformation | NIH | National Cancer Institute | 2022 to 2025 | $756,000 | September 1, 2022 | August 31, 2027 | PARRY, ERIN M | reporter.nih.gov |
| Enrichment of the State-1 Conformation of the HIV-1 Envelope Glycoprotein | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $750,826 | January 17, 2019 | December 31, 2022 | SODROSKI, JOSEPH G | reporter.nih.gov |
| De novo design of small-molecule-binding proteins | NIH | National Institute of General Medical Sciences | 2022 to 2024 | $747,000 | July 15, 2020 | July 31, 2025 | POLIZZI, NICHOLAS | reporter.nih.gov |
| Deep clinical trajectory modeling to optimize accrual to cancer clinical trials | NIH | National Cancer Institute | 2022 to 2024 | $746,997 | February 1, 2020 | January 31, 2026 | KEHL, KENNETH L | reporter.nih.gov |
| Mechanistic characterization of the anti-inflammatory function of thermogenic fat for the treatment of metabolic disorders | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2024 | $737,040 | March 15, 2022 | March 14, 2026 | MILLS, EVANNA LOUISA | reporter.nih.gov |
| Interrogating and rewiring cell signaling pathways in CAR-T cells with synthetic phosphotyrosine recognition domains | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 to 2024 | $732,593 | September 15, 2020 | January 31, 2025 | ZHOU, XIN | reporter.nih.gov |
| Characterizing genetic risk of cancer across diverse populations through multi-ancestry epigenome profiling and chromatin QTL discovery | NIH | National Cancer Institute | 2025 | $720,252 | April 1, 2025 | March 31, 2030 | BACA, SYLVAN C. | reporter.nih.gov |
| Hematopoietic stem cell gene therapy for infantile neuronal ceroid lipofuscinosis | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2022 | $717,826 | August 21, 2018 | April 30, 2023 | WILLIAMS, DAVID A | reporter.nih.gov |
| Expression and Impact of Interspersed Repeats | NIH | National Institute of General Medical Sciences | 2021 to 2022 | $708,000 | July 24, 2019 | May 31, 2023 | BURNS, KATHLEEN H | reporter.nih.gov |
| Single Molecule Detection of L1 Insertions and Intermediates | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $704,816 | April 1, 2023 | March 31, 2028 | BURNS, KATHLEEN H | reporter.nih.gov |
| The Center for Therapeutic Targeting of EWS-oncoproteins | NIH | National Cancer Institute | 2021 to 2022 | $703,677 | September 7, 2022 | June 30, 2024 | STEGMAIER, KIMBERLY | reporter.nih.gov |
| Improving prognosis prediction and therapy selection for cutaneous squamous cell carcinomas using artificial intelligence | NIH | National Institute of Biomedical Imaging and Bioengineering | 2024 | $693,156 | August 1, 2024 | July 31, 2027 | LOTTER, WILLIAM EDWARD | reporter.nih.gov |
| Survival Data Analysis using general censoring-free incident rate | NIH | National Institute of General Medical Sciences | 2024 to 2025 | $681,850 | March 1, 2024 | February 29, 2028 | UNO, HAJIME | reporter.nih.gov |
| Precision Assessment and Delivery of Cancer Risks in BRCA 1/2 Mutation Cancers | NIH | National Cancer Institute | 2021 | $676,046 | September 18, 2017 | August 31, 2023 | REBBECK, TIMOTHY R | reporter.nih.gov |
| Distance-based Exercise to preserve Function and prevENt Disability (DEFEND) | NIH | National Cancer Institute | 2024 to 2025 | $673,907 | September 18, 2024 | August 31, 2027 | LIGIBEL, JENNIFER A. | reporter.nih.gov |
| The Impact of Donor Hematopoietic DNMT3A Mutations in Stem Cell Transplant Recipients | NIH | National Cancer Institute | 2021 to 2023 | $659,712 | September 1, 2021 | July 14, 2024 | GIBSON, CHRISTOPHER JAMES | reporter.nih.gov |
| Prevention of HIV-1 transmission by small-molecule CD4-mimetic entry inhibitors | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $651,658 | July 14, 2017 | June 30, 2024 | MADANI, NAVID | reporter.nih.gov |
| Mapping the epigenetic dynamics of prostate cancer progression: integrating liquid biopsies and single-cell epigenomics for early detection of lineage plasticity and clinical decision-making | NIH | National Cancer Institute | 2025 | $627,474 | March 1, 2025 | February 28, 2030 | FREEDMAN, MATTHEW L | reporter.nih.gov |
| MUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung Cancer | NIH | National Cancer Institute | 2021 | $618,912 | April 1, 2012 | March 31, 2022 | KUFE, DONALD W. | reporter.nih.gov |
| Improving response prediction to neoadjuvant therapy in pancreatic cancer | NIH | National Cancer Institute | 2023 to 2025 | $605,166 | September 15, 2023 | October 1, 2025 | SINGH, HARSHABAD | reporter.nih.gov |
| A Novel Intervention for Avoidance-Related Opioid Misuse in Patients with Cancer | NIH | National Cancer Institute | 2022 to 2025 | $604,958 | July 1, 2022 | June 30, 2027 | YUSUFOV, MIRYAM | reporter.nih.gov |
| DMS/NIGMS 1: Statistical modeling and estimation of cellular population dynamics | NIH | National Institute of General Medical Sciences | 2021 to 2023 | $599,997 | September 22, 2021 | July 31, 2025 | MCDONALD, THOMAS | reporter.nih.gov |
| Molecular Dynamics of Glioma Formation and DNA Damage Response by Mutant IDH1 | NIH | National Cancer Institute | 2024 to 2025 | $598,806 | May 6, 2024 | August 31, 2025 | SHI, DIANA | reporter.nih.gov |
| The Center for Synovial Sarcoma Biology and Therapeutics | NIH | National Cancer Institute | 2021 to 2023 | $586,110 | April 1, 2023 | June 30, 2024 | KADOCH, CIGALL | reporter.nih.gov |
| Dissecting the role of DNA damage repair deficiency in Ewing sarcoma pathogenesis for improved risk stratification and treatment | NIH | National Cancer Institute | 2023 to 2025 | $579,581 | September 19, 2023 | August 31, 2028 | GILLANI, RIAZ | reporter.nih.gov |
| Young Empowered Scientists for ContinUed Research Engagement (YES for CURE) | NIH | National Cancer Institute | 2021 to 2023 | $575,729 | September 19, 2017 | August 31, 2024 | DECAPRIO, JAMES A. | reporter.nih.gov |
| Unlocking the Potential of PI3K Inhibition in CLL | NIH | National Cancer Institute | 2021 | $571,051 | March 1, 2017 | February 28, 2023 | BROWN, JENNIFER R | reporter.nih.gov |
| Systematic interrogation of the pancreatic cancer microenvironment in patient-derived specimens | NIH | National Cancer Institute | 2021 | $568,413 | September 30, 2017 | August 31, 2022 | HAHN, WILLIAM C. | reporter.nih.gov |
| MYB family alterations in pediatric gliomas | NIH | National Cancer Institute | 2021 | $554,504 | April 1, 2017 | March 31, 2023 | LIGON, KEITH LLOYD | reporter.nih.gov |
| The roles of anti-apoptotic proteins BCL-XL and MCL1 in mediating survival of high-grade serous ovarian cancer following drug-induced DNA damage | NIH | National Cancer Institute | 2021 to 2023 | $553,020 | July 1, 2019 | June 30, 2025 | STOVER, ELIZABETH HARMON | reporter.nih.gov |
| Spatial considerations in neuronal survival signals | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $545,358 | August 15, 2005 | April 30, 2023 | SEGAL, ROSALIND A. | reporter.nih.gov |
| (PQ8) Genetically faithful murine models for studying disease progression in chronic lymphocytic leukemia | NIH | National Cancer Institute | 2021 | $538,977 | May 11, 2017 | April 30, 2022 | WU, CATHERINE JU-YING | reporter.nih.gov |
| Functions of Cyclin/CDK complexes in development and cancer | NIH | National Cancer Institute | 2021 to 2023 | $538,854 | September 11, 2019 | August 31, 2024 | GENG, YAN | reporter.nih.gov |
| Disseminating an Evidence-Based Tobacco Control intervention for School Teachers in India | NIH | National Cancer Institute | 2021 | $538,246 | January 17, 2017 | December 31, 2023 | SORENSEN, GLORIAN C | reporter.nih.gov |
| Regulation of androgen receptor signaling in prostate cancer by protein arginine methylation | NIH | National Cancer Institute | 2025 | $536,161 | April 1, 2023 | March 31, 2028 | VISWANATHAN, SRINIVAS RAGHAVAN | reporter.nih.gov |
| Summer Program to Advance Research Careers (SPARC) | NIH | National Cancer Institute | 2021 to 2022 | $528,906 | September 8, 2017 | August 31, 2024 | BENZ, EDWARD J | reporter.nih.gov |
| PediQUEST: Improving Children's Quality of Life through e-PROMS and Palliative Care | NIH | National Institute of Nursing Research | 2021 | $524,144 | June 8, 2017 | December 31, 2022 | WOLFE, JOANNE | reporter.nih.gov |
| Targeting iron metabolism in pancreatic adenocarcinoma to overcome KRAS inhibitor therapeutic resistance | NIH | National Cancer Institute | 2025 | $523,480 | April 2, 2025 | March 31, 2030 | MANCIAS, JOSEPH D | reporter.nih.gov |
| Exploiting a Novel DNA Repair Defect in Ewing Sarcoma | NIH | National Cancer Institute | 2025 | $523,292 | December 4, 2024 | November 30, 2029 | D'ANDREA, ALAN D. | reporter.nih.gov |
| Validation and implementation of ctDNA as a clinically informative biomarkerin AYAs with sarcomas. | NIH | National Cancer Institute | 2024 to 2025 | $506,847 | August 1, 2024 | July 31, 2029 | SHULMAN, DAVID | reporter.nih.gov |
| Thermogenic chromatin remodeling control and fat tissue communication | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 | $503,865 | August 15, 2008 | March 31, 2023 | PUIGSERVER, PERE | reporter.nih.gov |
| Calling germline and mosaic variants from long genomic and RNA-seq reads | NIH | National Human Genome Research Institute | 2025 | $501,618 | September 1, 2025 | June 30, 2029 | LI, HENG | reporter.nih.gov |
| Dissecting Therapeutic Resistance and Progression in Metastatic Melanoma Through Clinical Computational Oncology | NIH | National Cancer Institute | 2021 to 2022 | $501,590 | September 18, 2018 | August 31, 2023 | LIU, DAVID | reporter.nih.gov |
| BCOR/PRC1.1 Inactivation In Splicing Factor Mutant MDS Progression | NIH | National Cancer Institute | 2024 to 2025 | $501,014 | April 8, 2024 | March 31, 2029 | VEDULA, RAHUL | reporter.nih.gov |
| Regulating proliferation and differentiation of erythroid progenitors | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $495,720 | July 1, 2020 | January 8, 2024 | LI, HOJUN | reporter.nih.gov |
| Reducing viral reservoirs by opening HIV-1 Env to antibody attack | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $495,256 | February 15, 2017 | August 31, 2023 | SODROSKI, JOSEPH G | reporter.nih.gov |
| Formation and function of pathologic stress granules containing RNA-Binding Protein SFPQ in tauopathy | NIH | National Institute on Aging | 2023 to 2024 | $489,500 | January 15, 2023 | December 31, 2024 | SEGAL, ROSALIND A. | reporter.nih.gov |
| Empowering NMR Utilization in Mechanistic Biology: Extending Size Limits and Catalyzing Automation | NIH | National Institute of General Medical Sciences | 2025 | $489,500 | August 1, 2025 | May 31, 2030 | ARTHANARI, HARIBABU | reporter.nih.gov |
| Integrative molecular dissection of acquired resistance to PD1/PD-L1 blockade in localized and metastatic urothelial carcinoma | NIH | National Cancer Institute | 2021 | $476,334 | May 1, 2021 | April 30, 2023 | SONPAVDE, GURU | reporter.nih.gov |
| Workshop on Research Methods in Supportive Oncology | NIH | National Cancer Institute | 2021 to 2025 | $475,557 | July 1, 2014 | January 31, 2030 | ROSENBERG, ABBY R | reporter.nih.gov |
| Integration of early genetic alterations and inflammation in gastroesophageal premalignancy | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $474,120 | April 1, 2019 | January 31, 2024 | SETHI, NILAY | reporter.nih.gov |
| Development of A Mindfulness-Based Mobile Health Intervention for Patients Coping with Pain from Advanced Malignancies | NIH | National Cancer Institute | 2022 to 2023 | $469,319 | April 1, 2022 | September 30, 2024 | ENZINGER, ANDREA C | reporter.nih.gov |
| Sexual Health and Rehabilitation (SHARE): An Online Educational Intervention for Young Adult Female Cancer Survivors | NIH | National Cancer Institute | 2024 to 2025 | $468,952 | June 1, 2024 | May 31, 2027 | BOBER, SHARON L. | reporter.nih.gov |
| Combined bromodomain and CDK4/6 inhibition in NUT Carcinoma and other solid tumors | NIH | National Cancer Institute | 2023 to 2024 | $463,885 | February 1, 2023 | January 31, 2025 | CHENG, MICHAEL L. | reporter.nih.gov |
| Expectations for Pediatric Cancer Treatment (EXPECT): A Family-Centered Intervention to Prepare Parents for Pediatric Leukemia Therapy | NIH | National Cancer Institute | 2021 to 2023 | $456,685 | September 19, 2019 | February 28, 2025 | GREENZANG, KATIE A. | reporter.nih.gov |
| Mesenchymal regulation of fetal intestinal development and adult regeneration | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $455,985 | July 17, 2020 | September 15, 2024 | MCCARTHY, NEIL | reporter.nih.gov |
| Advanced Workshop on Research Skills in Oncology | NIH | National Cancer Institute | 2023 to 2025 | $455,140 | April 1, 2020 | August 31, 2028 | THOMAS, JANE DELIMA | reporter.nih.gov |
| Defining the impact of mutational drivers on the immune microenvironment of CLL | NIH | National Cancer Institute | 2022 to 2023 | $453,523 | February 1, 2022 | January 31, 2024 | WU, CATHERINE JU-YING | reporter.nih.gov |
| Sleep Treatment Education Program-1 (STEP-1): A Randomized Trial of a Self-Management Insomnia Intervention for Cancer Survivors | NIH | National Cancer Institute | 2022 to 2023 | $453,523 | July 1, 2022 | June 30, 2025 | RECKLITIS, CHRISTOPHER JOHN | reporter.nih.gov |
| Translation initiation as a therapeutic target in neuroblastoma | NIH | National Cancer Institute | 2023 to 2024 | $453,511 | December 15, 2022 | November 30, 2024 | GEORGE, RANI E. | reporter.nih.gov |
| Investigating Interactions Between Radiation and Antibody-Drug Conjugates in Bladder Cancer | NIH | National Cancer Institute | 2024 to 2025 | $452,851 | April 1, 2024 | March 31, 2026 | MOUW, KENT W | reporter.nih.gov |
| Prolonged Nightly Fasting as a Behavioral Intervention for Obesity Reduction and the Prevention of Progression in Precursor Multiple Myeloma | NIH | National Cancer Institute | 2022 to 2023 | $452,690 | June 3, 2022 | May 31, 2025 | MARINAC, CATHERINE | reporter.nih.gov |
| Targeting the DNA Damage Response in CDK12-Mutant Prostate Cancer | NIH | National Cancer Institute | 2021 to 2022 | $451,611 | July 1, 2021 | June 30, 2023 | MOUW, KENT W | reporter.nih.gov |
| Chemical manipulation of creatine kinases to treat acute myeloid leukemia | NIH | National Cancer Institute | 2021 | $450,655 | April 1, 2021 | September 30, 2023 | CHOUCHANI, EDWARD THOMAS | reporter.nih.gov |
| MUC1-C is a target for advancing immunotherapy of non-small cell lung cancer | NIH | National Cancer Institute | 2024 | $450,429 | June 14, 2024 | May 31, 2026 | KUFE, DONALD W. | reporter.nih.gov |
| STEP-YA: An Online Self-Management Intervention for Young Adult Cancer Survivors with Insomnia | NIH | National Cancer Institute | 2022 to 2023 | $450,340 | June 1, 2022 | May 31, 2025 | RECKLITIS, CHRISTOPHER JOHN | reporter.nih.gov |
| Genetic dissection of neural pathways that modulate systemic inflammation | NIH | National Center for Complementary & Integrative Health | 2021 | $445,000 | September 16, 2019 | August 31, 2022 | MA, QIUFU | reporter.nih.gov |
| Molecular mechanisms of DNA double strand break repair by homologous recombination | NIH | National Institute of General Medical Sciences | 2025 | $445,000 | January 22, 2025 | December 31, 2029 | STINSON, BENJAMIN M | reporter.nih.gov |
| SESORRS endoscopy for the staging and evaluation of colorectal cancer | NIH | National Cancer Institute | 2024 to 2025 | $444,793 | June 8, 2022 | December 31, 2026 | NICOLSON, FAY | reporter.nih.gov |
| Targeting MUC1-C with an antibody drug conjugate for the therapy of advanced prostate cancer | NIH | National Cancer Institute | 2022 | $442,214 | September 22, 2022 | August 31, 2025 | KUFE, DONALD W. | reporter.nih.gov |
| Targeting MUC1-C for the Treatment of Small Cell Lung Cancer Progression | NIH | National Cancer Institute | 2022 to 2023 | $436,966 | February 4, 2022 | December 31, 2023 | KUFE, DONALD W. | reporter.nih.gov |
| Epigenetic regulators define a dynamic chromatin landscape in NUP98-rearranged leukemia | NIH | National Cancer Institute | 2024 to 2025 | $430,358 | April 1, 2024 | February 28, 2029 | HEIKAMP, EMILY | reporter.nih.gov |
| Regulation of the follicular T-cell response to autoimmunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $429,521 | April 1, 2000 | November 30, 2022 | CANTOR, HARVEY | reporter.nih.gov |
| Academic Career Skills for Junior Faculty Researchers | NIH | National Cancer Institute | 2021 to 2022 | $420,692 | April 1, 2020 | August 31, 2023 | PIRL, WILLIAM F | reporter.nih.gov |
| Exploring alternate targets for inhibition of virus infection by PPI disruption | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $419,995 | February 22, 2021 | January 31, 2024 | CALDERWOOD, MICHAEL A | reporter.nih.gov |
| The ALK receptor tyrosine kinase as a therapeutic target in neuroblastoma | NIH | National Cancer Institute | 2021 | $413,844 | January 1, 2011 | February 28, 2023 | GEORGE, RANI E. | reporter.nih.gov |
| Impact of preanalytical conditions on functional cancer biomarkers | NIH | National Cancer Institute | 2025 | $406,351 | December 1, 2025 | November 30, 2030 | BHOLA, PATRICK | reporter.nih.gov |
| Insights from somatic genomics lead to novel therapeutic targets in inherited bone marrow failure syndromes: Shwachman-Diamond Syndrome as a model. | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $406,143 | July 1, 2021 | August 31, 2023 | KENNEDY, ALYSSA | reporter.nih.gov |
| Development and Pilot Testing of a Collaborative Agenda-Setting Intervention to Promote Patient-Centered Communication in Ovarian Cancer Care | NIH | National Institute of Nursing Research | 2023 to 2025 | $401,474 | May 15, 2023 | April 30, 2027 | POZZAR, RACHEL | reporter.nih.gov |
| Integrative modelling of single-cell data to elucidate the genetic architecture of complex disease | NIH | National Human Genome Research Institute | 2023 | $400,000 | September 21, 2023 | July 31, 2024 | GUSEV, ALEXANDER | reporter.nih.gov |
| Dissecting the Pathogenesis of Ewing Sarcoma with Integrative Genomics | NIH | National Cancer Institute | 2021 | $396,547 | January 1, 2017 | June 30, 2022 | STEGMAIER, KIMBERLY | reporter.nih.gov |
| Investigating 53BP1 'dephosphorylation' as a critical determinant of PARP | NIH | National Cancer Institute | 2021 | $384,923 | March 15, 2017 | February 28, 2023 | CHOWDHURY, DIPANJAN | reporter.nih.gov |
| Repurposing Metformin for the Prevention of Disease Progression in Precursor Multiple Myeloma | NIH | National Cancer Institute | 2021 to 2022 | $384,480 | September 1, 2020 | February 29, 2024 | MARINAC, CATHERINE | reporter.nih.gov |
| Perturbation based single cell investigation of tumor micro-environment | NIH | National Cancer Institute | 2022 to 2025 | $380,515 | August 3, 2020 | July 31, 2026 | ZHANG, CHI | reporter.nih.gov |
| Investigating Immune Responses to Neoantigen Cancer Vaccines using In Vivo Functionalized Lineage | NIH | National Cancer Institute | 2022 to 2025 | $376,785 | February 1, 2022 | December 31, 2025 | ROBLES-OTEIZA, CAMILA | reporter.nih.gov |
| Inhibitor-sensitive and -resistant EGFR mutants from lung cancer and glioblastoma | NIH | National Cancer Institute | 2021 to 2022 | $368,739 | March 24, 2006 | March 31, 2023 | ECK, MICHAEL J | reporter.nih.gov |
| Degrading therapeutically important kinases using small molecules | NIH | National Cancer Institute | 2021 | $365,491 | December 1, 2018 | March 31, 2021 | GRAY, NATHANAEL SCHIANDER | reporter.nih.gov |
| Targeting Oncogenic Drivers in Cancer | NIH | National Cancer Institute | 2022 to 2025 | $365,310 | March 7, 2022 | February 28, 2026 | BOUDREAU, MATTHEW W | reporter.nih.gov |
| Effects of Extracellular Mechanics on Mechanosensory and Central Neuron Function | NIH | National Institute on Aging | 2022 to 2025 | $358,155 | September 23, 2019 | December 31, 2025 | FRANCO, JOY ANN | reporter.nih.gov |
| New Chemical Tools for Covalent Drug Discovery | NIH | National Cancer Institute | 2024 to 2025 | $354,873 | February 1, 2024 | June 1, 2025 | MARTO, JARROD A. | reporter.nih.gov |
| Targeting mitochondrial one carbon folate metabolism for novel T-cell acute lymphoblastic leukemia therapy | NIH | National Cancer Institute | 2021 to 2022 | $354,240 | February 15, 2018 | January 31, 2023 | PIKMAN, YANA | reporter.nih.gov |
| The Promoting Resilience in Stress Management (PRISM) Intervention: a multi-site randomized controlled trial for Adolescents and Young Adults with advanced cancer | NIH | National Cancer Institute | 2023 | $351,683 | July 29, 2023 | July 31, 2025 | ROSENBERG, ABBY R | reporter.nih.gov |
| Defining the landscape and mechanisms of protein redox regulation during aging | NIH | National Institute on Aging | 2021 | $343,865 | April 15, 2021 | March 31, 2022 | CHOUCHANI, EDWARD THOMAS | reporter.nih.gov |
| Mitochondrial Protein Translation Signaling and Survival Mechanisms | NIH | National Institute on Aging | 2021 | $337,842 | September 1, 2021 | November 30, 2023 | PUIGSERVER, PERE | reporter.nih.gov |
| Modeling and Dissecting Epigenetic Drivers of Gliomagenesis | NIH | National Cancer Institute | 2022 to 2023 | $334,800 | March 1, 2022 | August 31, 2023 | RAHME, GILBERT J | reporter.nih.gov |
| Identifying metabolic regulation of T cells during early childhood development | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2024 to 2025 | $330,480 | April 1, 2024 | March 31, 2029 | ROWE, JARED H. | reporter.nih.gov |
| Inflammatory Disease Associations in Clonal Hematopoiesis | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $330,112 | September 1, 2024 | August 31, 2029 | WEEKS, LACHELLE DAWN | reporter.nih.gov |
| Dissecting the Role of Germline Genetics in RAS-Driven Cancers | NIH | National Cancer Institute | 2024 to 2025 | $327,456 | February 1, 2024 | August 31, 2025 | COLLINS, RYAN LEWIS | reporter.nih.gov |
| The Role of Mitochondrial TNAP in Adaptive Thermogenesis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $327,368 | December 1, 2022 | August 8, 2025 | SUN, YIZHI | reporter.nih.gov |
| Tools for DUB Drug Discovery | NIH | National Cancer Institute | 2021 | $323,910 | May 15, 2020 | April 30, 2023 | MARTO, JARROD A. | reporter.nih.gov |
| Integrating pain-CBT into an mHealth analgesic support intervention for patients withchronic pain from advanced cancers | NIH | National Cancer Institute | 2024 to 2025 | $319,265 | December 17, 2024 | June 30, 2027 | HILTON, DESIREE R | reporter.nih.gov |
| Investigating molecular mechanism of immune response during cancer progression | NIH | National Cancer Institute | 2021 to 2024 | $316,083 | September 8, 2018 | November 30, 2024 | CHEN, ZEYU | reporter.nih.gov |
| Obesity and Pancreatic Cancer Progression and Survival | NIH | National Cancer Institute | 2021 to 2022 | $299,393 | July 4, 2018 | June 30, 2024 | BABIC, ANA | reporter.nih.gov |
| Improving Hospice Use for Patients with Blood Cancers | NIH | National Cancer Institute | 2021 to 2022 | $296,978 | September 1, 2017 | May 31, 2023 | ODEJIDE, OREOFE OLUKEMI | reporter.nih.gov |
| Functional Characterization of HER Family Variant Biology and Resistance in Cancer | NIH | National Cancer Institute | 2021 to 2022 | $285,984 | September 15, 2021 | August 31, 2023 | HAYES, TIKVAH K | reporter.nih.gov |
| Integrative Prediction of Therapeutic Response in T-cell Lymphoma by Omic and Spatial Modeling | NIH | National Cancer Institute | 2021 to 2022 | $272,160 | March 1, 2021 | February 28, 2023 | NIRMAL, AJIT JOHNSON | reporter.nih.gov |
| Characterizing the role of MARCH5 in apoptosis regulation in acute myeloid leukemia | NIH | National Cancer Institute | 2021 to 2022 | $272,160 | August 23, 2021 | July 31, 2023 | LIN, SHAN | reporter.nih.gov |
| Targeting mechanical regulation of monocyte fate in head and neck cancer. | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2022 | $270,000 | April 1, 2021 | June 30, 2022 | VINING, KYLE HOLMBERG | reporter.nih.gov |
| In vivo testing of an agonistic anti-GITR mAb that induces cell surface clustering to augment signal transduction and a 2nd Gen bispecific anti-GITR/PD1 Ab derivative for improved anti-tumor activity | NIH | National Cancer Institute | 2024 | $268,059 | February 1, 2024 | January 31, 2027 | MARASCO, WAYNE A. | reporter.nih.gov |
| Targeting the CDK4/6 pathway in MiT/TFE-translocation renal cell carcinoma | NIH | National Cancer Institute | 2025 | $267,298 | February 1, 2025 | January 31, 2027 | VISWANATHAN, SRINIVAS RAGHAVAN | reporter.nih.gov |
| SESORRS endoscopy for the staging and evaluation of colorectal cancer | NIH | National Cancer Institute | 2022 to 2023 | $266,978 | June 8, 2022 | December 31, 2023 | NICOLSON, FAY | reporter.nih.gov |
| Targeting Menin Protein Stability In AML | NIH | National Cancer Institute | 2023 to 2024 | $259,200 | July 18, 2023 | February 28, 2025 | CUTLER, JEVON | reporter.nih.gov |
| Targeting mitochondrial vulnerabilities to drive intrinsic melanoma immunogenicity | NIH | National Cancer Institute | 2024 to 2025 | $257,596 | April 4, 2024 | July 1, 2025 | LIANG, JIAXIN | reporter.nih.gov |
| Collaborative Care to Improve Resilience and Quality of Life among Youth with Non-malignant Blood Disorders | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $252,946 | September 1, 2024 | August 31, 2029 | ROSENBERG, ABBY R | reporter.nih.gov |
| Defining clinically relevant transcriptional networks in gastrointestinal stromal tumor | NIH | National Cancer Institute | 2021 to 2022 | $251,631 | August 1, 2020 | August 31, 2022 | HEMMING, MATTHEW | reporter.nih.gov |
| Mechanistic Determinants of Follicular-Helper T-cell Lymphomagenesis | NIH | National Cancer Institute | 2021 | $250,577 | July 1, 2019 | June 30, 2022 | NG, SAMUEL YAO-MING | reporter.nih.gov |
| Dissecting the Role of Germline Genetics in RAS-Driven Cancers | NIH | National Cancer Institute | 2025 | $248,999 | February 1, 2024 | August 31, 2028 | COLLINS, RYAN LEWIS | reporter.nih.gov |
| Memory-like NK cells for enhanced immunotherapy of post transplant relapse in patients with myeloid malignancies | NIH | National Cancer Institute | 2021 | $248,243 | January 1, 2020 | December 31, 2021 | ROMEE, RIZWAN | reporter.nih.gov |
| Immune Evasion through HLA-E in Diffuse Large B-Cell Lymphoma: Defining Its Regulation and Cellular Interactions | NIH | National Cancer Institute | 2025 | $241,884 | September 3, 2025 | August 31, 2030 | HAHN, CYNTHIA | reporter.nih.gov |
| Advancing WRN as a synthetic lethal target for microsatellite unstable Cancers | NIH | National Cancer Institute | 2021 | $237,994 | September 1, 2021 | August 31, 2022 | CHAN, EDMOND | reporter.nih.gov |
| Elucidating the Mechanisms of Translational Approaches to Enhance Recovery of Aged Muscle | NIH | National Institute on Aging | 2023 to 2025 | $237,953 | September 15, 2021 | August 31, 2027 | PETROCELLI, JONATHAN JOSEPH | reporter.nih.gov |
| Mechanism of Action of Spautin-1, A Novel Degrader of IKZF1 | NIH | National Cancer Institute | 2021 | $228,182 | July 1, 2020 | June 30, 2022 | KODURI, VIDYASAGAR | reporter.nih.gov |
| Determining Mechanisms and Measures for the Design of Chemotherapy-Induced Peripheral Neuropathy Clinical Trials in Adolescents and Young Adults with Cancer | NIH | National Institute of Nursing Research | 2021 to 2022 | $227,399 | May 4, 2020 | October 31, 2023 | KNOERL, ROBERT JAMES | reporter.nih.gov |
| Deciphering non-canonical translation in high risk medulloblastoma | NIH | National Cancer Institute | 2022 | $226,800 | September 1, 2022 | March 31, 2023 | PRENSNER, JOHN | reporter.nih.gov |
| Targeting the cancer neo-genome for destruction with CRISPR-Cas enzymes | NIH | National Cancer Institute | 2023 to 2025 | $221,404 | July 1, 2023 | June 30, 2026 | LEIBOWITZ, MITCHELL L | reporter.nih.gov |
| Fast-kinetics approaches to define direct gene-regulatory functions of MYB in leukemia | NIH | National Cancer Institute | 2023 | $220,792 | August 1, 2023 | December 12, 2023 | PIMKIN, MAXIM | reporter.nih.gov |
| Defining the landscape and mechanisms of redox regulation of metabolism during aging | NIH | National Institute on Aging | 2022 to 2023 | $219,858 | May 15, 2022 | December 31, 2024 | XIAO, HAOPENG | reporter.nih.gov |
| Biomaterial Drones for Image-Guided Drug Delivery during radiotherapy | NIH | National Cancer Institute | 2021 | $211,789 | February 15, 2019 | June 30, 2021 | NGWA, WILFRED | reporter.nih.gov |
| Lipid metabolism as a therapeutic vulnerability in BET inhibitor-resistant medulloblastoma | NIH | National Cancer Institute | 2021 to 2023 | $205,268 | April 1, 2021 | March 31, 2024 | LUPIEN, LESLIE | reporter.nih.gov |
| Cancer Therapeutic Resistance: Implication of AcAPE1 Mediated DNA Repair and T-Cell Based Immunotherapy | NIH | National Cancer Institute | 2021 to 2022 | $204,178 | September 1, 2019 | August 31, 2023 | ROYCHOUDHURY, SHRABASTI | reporter.nih.gov |
| Fertility legislation and unmet needs: Exploring intervenable barriers for quality oncofertility care among adolescent and young adult cancer patients | NIH | National Cancer Institute | 2024 to 2025 | $202,342 | September 1, 2023 | April 30, 2028 | STAL, JULIA | reporter.nih.gov |
| Targeting ALK through Degradation and Allosteric Inhibitors | NIH | National Cancer Institute | 2021 | $199,385 | May 15, 2009 | March 31, 2021 | GRAY, NATHANAEL SCHIANDER | reporter.nih.gov |
| Elucidating novel molecular mechanisms of irisin-mediated effects via integrin | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2024 | $196,102 | May 1, 2022 | December 31, 2024 | A, MU | reporter.nih.gov |
| The role of CMTR2 in Lung Cancer | NIH | National Cancer Institute | 2021 to 2022 | $195,178 | September 21, 2016 | December 31, 2023 | YERMALOVICH, ALENA | reporter.nih.gov |
| Metabolically active macrophages: a novel link between obesity and triple negative breast cancer | NIH | National Cancer Institute | 2021 to 2022 | $195,178 | December 21, 2018 | November 30, 2023 | TIWARI, PAYAL | reporter.nih.gov |
| Elucidating the role of RNA splicing in the metastatic seeding and outgrowth of aggressive cancers. | NIH | National Cancer Institute | 2024 to 2025 | $193,342 | July 13, 2022 | June 30, 2028 | PARKER, KIMBERLY | reporter.nih.gov |
| SIRT1 Regulates RNA Stability to Promote Breast Cancer | NIH | National Cancer Institute | 2024 to 2025 | $193,342 | August 1, 2022 | May 31, 2028 | WANG, FANGYU | reporter.nih.gov |
| Noninvasive monitoring and evaluation of anti-tumor responses as a predictive tool | NIH | National Cancer Institute | 2021 | $191,276 | June 1, 2019 | May 31, 2022 | RASHIDIAN, MOHAMMAD | reporter.nih.gov |
| Structural biology and drug discovery targeting oncogenic EGFR and BRAF kinases | NIH | National Cancer Institute | 2021 | $188,413 | September 19, 2017 | July 22, 2022 | PARK, EUNYOUNG | reporter.nih.gov |
| Translational regulation of PGC1alpha and oxidative metabolism | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $180,000 | May 1, 2021 | April 30, 2024 | DUMESIC, PHILLIP ANTHONY | reporter.nih.gov |
| Mechanisms of mitochondrial-ER communication during dietary and thermal induced stress | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2024 | $180,000 | July 1, 2023 | June 30, 2025 | LATORRE MURO, PEDRO ANTONIO | reporter.nih.gov |
| A Preventive Care Approach to Mitigate the Impact of Pediatric ALL Treatment on Sleep | NIH | National Cancer Institute | 2021 to 2022 | $178,000 | April 1, 2021 | March 31, 2024 | ZHOU, ERIC S | reporter.nih.gov |
| Repurposing Bruton's tyrosine kinase (BTK) inhibitors to reverse immunosuppression in high-grade serous ovarian cancer (HGSC) | NIH | National Cancer Institute | 2022 to 2023 | $178,000 | July 7, 2022 | June 30, 2024 | GLIMCHER, LAURIE HOLLIS | reporter.nih.gov |
| Overcoming resistance in BCR-ABL-rearranged acute lymphoblastic leukemia | NIH | National Cancer Institute | 2021 | $177,120 | August 1, 2017 | July 31, 2022 | MURAKAMI, MARK A. | reporter.nih.gov |
| Functional interrogation of epigenetic vulnerabilities in KRAS-mutant pancreatic cancer | NIH | National Cancer Institute | 2021 | $177,120 | September 1, 2017 | August 31, 2022 | AGUIRRE, ANDREW JAMES | reporter.nih.gov |
| New Therapeutic Targets in Small Cell Lung Cancer that are Epistatic or Synthetic Lethal with pRB Loss | NIH | National Cancer Institute | 2021 | $177,120 | September 19, 2017 | August 31, 2022 | OSER, MATTHEW GILBERT | reporter.nih.gov |
| Investigating the effect of ERCC2 mutations on DNA repair capacity and chemo-radiotherapy response in muscle-invasive bladder cancer | NIH | National Cancer Institute | 2021 | $176,947 | August 1, 2017 | July 31, 2022 | MOUW, KENT W | reporter.nih.gov |
| Curated prostate cancer data for novel and reproducible prognostic modeling | NIH | National Cancer Institute | 2021 | $173,649 | March 1, 2020 | February 28, 2023 | TYEKUCHEVA, SVITLANA | reporter.nih.gov |
| Resolving phenotypic overlap in renal carcinoma subtypes using multi-tiered network methods | NIH | National Cancer Institute | 2025 | $172,193 | May 7, 2025 | April 30, 2030 | BEN GUEBILA, MAROUEN | reporter.nih.gov |
| Dissecting the impact of tumor-immune spatial interactions in mismatch-repair stratified colorectal cancers | NIH | National Cancer Institute | 2025 | $170,641 | August 1, 2025 | July 31, 2027 | WALA, JEREMIAH | reporter.nih.gov |
| Uncovering Principles of Adaptive Regulation in Cancer Resistance Through Deep Evolutionary Profiling | NIH | National Cancer Institute | 2021 | $170,640 | July 1, 2020 | June 30, 2024 | RAVI, ARVIND | reporter.nih.gov |
| The Role of Histone Cleavage in Breast Cancer | NIH | National Cancer Institute | 2025 | $170,640 | July 1, 2025 | June 30, 2027 | LI, ZHEQI | reporter.nih.gov |
| Deep clinical trajectory modeling to optimize accrual to cancer clinical trials | NIH | National Cancer Institute | 2021 | $170,176 | February 1, 2020 | January 31, 2022 | KEHL, KENNETH L | reporter.nih.gov |
| Robust and cost-effective computational methods for haplotype-resolved genome assemblies | NIH | National Human Genome Research Institute | 2023 to 2024 | $165,150 | February 13, 2023 | July 1, 2024 | CHENG, HAOYU | reporter.nih.gov |
| Harnessing Exercise to Enhance Immunity and Boost Immunotherapy Outcomes in Patients with Lung Cancer | NIH | National Cancer Institute | 2024 | $163,448 | February 1, 2024 | December 31, 2024 | KANG, DONG-WOO | reporter.nih.gov |
| Signaling pathways in tumoricidal macrophages in pancreatic cancer | NIH | National Cancer Institute | 2025 | $159,304 | July 1, 2025 | June 30, 2027 | QIANG, LI | reporter.nih.gov |
| CAREER: Synthesis and Application of Bioorthogonally Degradable Polymers | NSF | Division Of Chemistry | 2023 | $157,741 | April 1, 2023 | November 30, 2024 | Justin Kim | nsf.gov |
| The mechanistic study on irisin-mediated immune response and its role in adipose tissue dynamics | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $152,454 | January 1, 2025 | November 30, 2027 | A, MU | reporter.nih.gov |
| Mitochondria mediated intercellular metabolic coupling in bone marrow regeneration | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 | $150,000 | September 1, 2024 | August 31, 2025 | CANCELAS, JOSE A. | reporter.nih.gov |
| Mechanistic Understanding of Hypoxia-Induced Peroxisome loss: Implications for Heart Failure | NIH | National Heart, Lung, and Blood Institute | 2022 | $149,850 | June 1, 2022 | June 30, 2023 | WYANT, GREG | reporter.nih.gov |
| Defining PRC1.1 as a gatekeeper of lineage plasticity and response to anti-GD2 therapy | NIH | National Cancer Institute | 2023 | $147,150 | May 9, 2023 | May 31, 2024 | MABE, NATHANIEL | reporter.nih.gov |
| Structure and Function of the SHOC2 Holophosphatase Complex in RAS-driven Cancer | NIH | National Cancer Institute | 2023 | $147,150 | May 1, 2023 | December 1, 2023 | KWON, JASON | reporter.nih.gov |
| Identifying Combination Therapies in Ovarian Tumors using High Throughput Dynamic BH3 Profiling | NIH | National Cancer Institute | 2022 to 2023 | $143,574 | December 1, 2020 | March 31, 2024 | MCQUEENEY, KELLEY | reporter.nih.gov |
| Evaluating the mechanism by which the DYNLL1-MRE11 complex regulates DNA end resection and genome stability. | NIH | National Institute of General Medical Sciences | 2023 to 2024 | $143,364 | February 1, 2023 | January 31, 2025 | SWIFT, MICHELLE | reporter.nih.gov |
| Defining IKZF1/IKAROS as an oncogene and therapeutic target in MLL-r AML | NIH | National Cancer Institute | 2021 to 2022 | $138,692 | June 1, 2020 | May 31, 2023 | CUTLER, JEVON | reporter.nih.gov |
| Engineered Living Materials as Programmable Therapeutic Implants for Pancreatic Cancer | NIH | National Cancer Institute | 2025 | $137,995 | September 2, 2025 | August 31, 2026 | HARIMOTO, TETSUHIRO | reporter.nih.gov |
| Elucidating the Role of Epigenetic Plasticity in anti-GD2 Immunotherapy Response | NIH | National Cancer Institute | 2021 to 2022 | $137,784 | June 1, 2021 | May 31, 2024 | MABE, NATHANIEL | reporter.nih.gov |
| Therapeutic Strategies to Prevent Small Cell Lung Cancer Histological Transformation | NIH | National Cancer Institute | 2025 | $136,266 | July 14, 2025 | June 30, 2027 | LI, YIXIANG | reporter.nih.gov |
| Structural Basis for Small Molecule-Mediated Allosteric Activation of Protein Phosphatase 2A | NIH | National Cancer Institute | 2021 | $136,080 | May 3, 2021 | July 15, 2021 | MORITA, KEN | reporter.nih.gov |
| A pan-cancer atlas of driver mutations in >100,000 patients based on a hypothesis-driven combined computational and experimental approach | NIH | National Cancer Institute | 2021 | $133,195 | August 16, 2021 | March 31, 2022 | DIETLEIN, FELIX | reporter.nih.gov |
| Studies of mutant-selective allosteric inhibitors of EGFR for non-small cell lung cancer | NIH | National Cancer Institute | 2021 to 2022 | $130,728 | June 4, 2020 | April 29, 2023 | BEYETT, TYLER STEVEN | reporter.nih.gov |
| Targeting casein kinase 1-alpha for cancer therapy | NIH | National Cancer Institute | 2021 | $130,475 | July 6, 2018 | February 28, 2022 | CORSELLO, STEVEN MUNTEAN | reporter.nih.gov |
| The role of the mesenchymal niche in intestinal crypt fission | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 | $125,700 | March 1, 2024 | September 15, 2024 | MCCARTHY, NEIL | reporter.nih.gov |
| Towards a structural understanding of transcriptional regulation by ZMYM2-KDM1A-CoREST | NIH | National Institute of General Medical Sciences | 2025 | $125,000 | December 18, 2024 | November 30, 2026 | WACHTER, FRANZISKA | reporter.nih.gov |
| Identifying drug synergistic with cancer immunotherapy | NIH | National Cancer Institute | 2021 | $120,038 | September 16, 2020 | December 31, 2022 | SAHU, AVINASH DAS | reporter.nih.gov |
| Revealing Cellular Determinants of LINE-1 Retrotransposition Outcomes | NIH | National Institute of General Medical Sciences | 2025 | $109,448 | September 1, 2025 | August 31, 2027 | LAW, CHEUK-TING | reporter.nih.gov |
| The Role of E2F2 in HER2 Positive Breast Cancer | NIH | National Cancer Institute | 2021 | $104,406 | August 1, 2018 | July 31, 2022 | RENNHACK, JONATHAN | reporter.nih.gov |
| Evaluating METTL1-mediated m7G tRNA methylation as a novel dependency in alveolar rhadomyosarcoma | NIH | National Cancer Institute | 2025 | $99,576 | September 1, 2023 | March 31, 2029 | WILKINSON, EMMA ANNE | reporter.nih.gov |
| Exploiting Oncogenic Chromatin Regulators in Cancer Initiation and Progression | NIH | National Cancer Institute | 2024 | $99,216 | September 1, 2021 | September 1, 2024 | HYDER, USMAN | reporter.nih.gov |
| Defining Therapeutically Targetable Regulators of Tumor-Intrinsic Immune Suppression in Glioblastoma | NIH | National Cancer Institute | 2025 | $99,216 | February 7, 2025 | January 31, 2029 | JOHNSON, AMANDA | reporter.nih.gov |
| BH3 Profiling in AML to Measure Apoptotic Signaling Kinetics of Approved Drugs and Identify Integrated Stress Response Apoptotic Susceptibilities | NIH | National Cancer Institute | 2025 | $99,216 | August 10, 2023 | July 31, 2029 | UNG, JOHNSON | reporter.nih.gov |
| Investigating IGF2BP1 as a novel Therapeutic Target for Ewing Sarcoma | NIH | National Cancer Institute | 2024 to 2025 | $95,155 | April 3, 2024 | July 25, 2025 | BOND, MICHAEL JOSEPH | reporter.nih.gov |
| Mechanisms and therapeutic evaluation of splicing modulation for cohesin-mutant myelodysplastic syndromes | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $95,149 | September 1, 2021 | January 31, 2023 | WHEELER, EMILY | reporter.nih.gov |
| Targeting the Nrf2 pathway in cancer | NIH | National Cancer Institute | 2021 | $93,462 | May 1, 2020 | May 14, 2021 | ZHANG, DI | reporter.nih.gov |
| Understanding Ancestral Contribution to Lung Adenocarcinoma | NIH | National Cancer Institute | 2021 | $91,460 | April 1, 2021 | January 15, 2022 | ZHANG, JIAN | reporter.nih.gov |
| Mechanistic characterization of the anti-inflammatory function of thermogenic fat for the treatment of metabolic disorders | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 | $90,000 | July 10, 2020 | March 1, 2022 | MILLS, EVANNA LOUISA | reporter.nih.gov |
| Remodeling mitochondrial cristae to rescue bioenergetic defects in mitochondrial disease | NIH | National Institute of General Medical Sciences | 2021 to 2022 | $88,702 | April 1, 2020 | June 10, 2022 | MUTLU, BESTE | reporter.nih.gov |
| Expanding the understanding of tRNA lifecycle under cellular stress | NIH | National Institute of General Medical Sciences | 2025 | $78,040 | September 1, 2025 | August 31, 2027 | WILLIAMS, ALLISON | reporter.nih.gov |
| Elucidating the role of PATZ1 in MYCN-amplified neuroblastoma | NIH | National Cancer Institute | 2025 | $78,040 | September 5, 2025 | September 4, 2028 | SOEUNG, MELINDA | reporter.nih.gov |
| Dissecting the Structure of Oligomeric BAK and the Implications for Reactivating Apoptosis in Cancer | NIH | National Cancer Institute | 2025 | $75,520 | September 15, 2025 | September 14, 2027 | MA, MINH THU H | reporter.nih.gov |
| Interrogating the role of IFNgamma in promoting metastasis and immune evasion of triple negative breast cancer | NIH | National Cancer Institute | 2025 | $75,520 | August 1, 2025 | July 31, 2028 | GETZLER, ADAM JOSHUA | reporter.nih.gov |
| Examining the role of adenosine-sensing by macrophages in obesity-induced cardiac inflammation | NIH | National Heart, Lung, and Blood Institute | 2025 | $75,052 | September 30, 2025 | September 29, 2028 | SPRENKLE, NEIL | reporter.nih.gov |
| Elucidating the role of the SAGA complex in MYCN-amplified neuroblastoma | NIH | National Cancer Institute | 2021 | $74,886 | September 12, 2019 | September 11, 2022 | MALONE, CLARE FELICITY | reporter.nih.gov |
| Mismatch Repair Proteins as Drivers of Temozolomide Resistance in Glioblastoma | NIH | National Cancer Institute | 2021 | $70,458 | July 1, 2019 | June 30, 2022 | BOYNTON, ADAM NATHANIEL | reporter.nih.gov |
| Elucidating the role of SHOC2 to enhance MEK inhibitor sensitivity in pancreatic cancer | NIH | National Cancer Institute | 2021 | $66,390 | July 1, 2019 | June 30, 2022 | KWON, JASON | reporter.nih.gov |
| COVID Extension: Material Hardship as a Targetable Measure of Poverty in Pediatric Cancer | NIH | National Cancer Institute | 2021 | $63,388 | September 1, 2021 | February 28, 2022 | BONA, KIRA O. | reporter.nih.gov |
| Deciphering the mechanisms regulating itaconate production and signaling in macrophages | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $47,945 | September 1, 2025 | August 31, 2028 | TRAN, NHIEN | reporter.nih.gov |
| Role of PPM1D and PPM1D mutations in hematopoiesis and response to stress | NIH | National Cancer Institute | 2021 | $46,239 | August 20, 2021 | January 1, 2022 | MILLER, PETER GRANT | reporter.nih.gov |
| Conference: Symposium on the Immune System of Bacteria | NSF | Division of Molecular and Cellular Biosciences | 2024 | $45,000 | March 1, 2024 | February 28, 2025 | Philip Kranzusch | nsf.gov |
| SIMPRO Research Center: Integration and Implementation of PROs for Symptom Manage | NIH | National Cancer Institute | 2023 | $42,500 | September 20, 2018 | August 31, 2024 | HASSETT, MICHAEL JAMES | reporter.nih.gov |
| Unraveling the Mechanisms of Neoantigen Vaccine-Induced Epitope Spreading | NIH | National Cancer Institute | 2025 | $36,538 | July 1, 2025 | June 30, 2028 | RICHTERICH, CONNOR ANTONIO | reporter.nih.gov |
| Epigenetic Induction of Gliomagenesis in Neural Progenitor Cells | NIH | National Cancer Institute | 2021 | $27,562 | January 1, 2019 | July 2, 2022 | RAHME, GILBERT J | reporter.nih.gov |
| Contributions of tumor molecular subtypes to prostate cancer racial disparities | NIH | National Cancer Institute | 2021 | $26,717 | February 1, 2020 | March 31, 2021 | KENSLER, KEVIN HUGHES | reporter.nih.gov |
| Characterization of LINE-1 reverse transcriptase activity | NIH | National Institute of General Medical Sciences | 2023 | $22,942 | February 2, 2023 | May 11, 2023 | SMAIL, BENEDICT | reporter.nih.gov |
| Leveraging mHealth to deliver integrated pain-CBT, opioid monitoring, and self-management support for advanced cancer patients coping with chronic pain | NIH | National Cancer Institute | 2023 | $22,705 | October 7, 2024 | June 30, 2025 | AZIZODDIN, DESIREE R | reporter.nih.gov |
| Structural and functional investigation into protein degradation by the DCAF16 ubiquitin ligase | NIH | National Cancer Institute | 2021 | $15,515 | January 3, 2022 | February 18, 2022 | PUVAR, KEDAR | reporter.nih.gov |
| Symposium on the Immune System of Bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $7,500 | March 5, 2024 | February 28, 2025 | KRANZUSCH, PHILIP J | reporter.nih.gov |
| Investigating SLC46A3 as a negative regulator of nanoparticle drug delivery | NIH | National Cancer Institute | 2024 | $1 | July 5, 2024 | September 30, 2024 | STRAEHLA, JOELLE PAYNE | reporter.nih.gov |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 221 | $176,991,681 | 0 | $0 |
| 2024 | 236 | $163,860,662 | 1 | $45,000 |
| 2023 | 233 | $162,771,697 | 1 | $157,741 |
| 2022 | 243 | $157,477,180 | 0 | $0 |
| 2021 | 253 | $160,221,256 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|---|---|---|---|---|---|
| Change of Recipient Organization (Type 7 Parent Clinical Trial Optional) | PA-24-254 | NIH | July 12, 2027 | Not listed | Notice number printed on 3 awards here | |
| NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed) | PA-24-194 | NIH | May 7, 2027 | Not listed | Notice number printed on 3 awards here | |
| Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Not Allowed) | PA-24-182 | NIH | May 8, 2027 | Not listed | Notice number printed on 1 award here | |
| NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed) | PAR-27-089 | NIH | 93.398 | November 2, 2026 | Not listed | Same assistance listing 93.398 as 106 awards here |
| NCI Research Specialist Award for Core and Laboratory-based Scientists (R50 Clinical Trial Not Allowed) | PAR-27-088 | NIH | 93.398 | November 20, 2026 | Not listed | Same assistance listing 93.398 as 106 awards here |
| Emerging Global Leader Award (K43 Independent Clinical Trial Required) | PAR-24-295 | NIH | 93.398 | December 3, 2026 | Not listed | Same assistance listing 93.398 as 106 awards here |
| Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed) | PAR-24-296 | NIH | 93.398 | December 3, 2026 | Not listed | Same assistance listing 93.398 as 106 awards here |
| NIH Research Software Engineer (RSE) Award (R50 Clinical Trials Not Allowed) | RFA-OD-24-011 | NIH | 93.398 | December 4, 2026 | Not listed | Same assistance listing 93.398 as 106 awards here |
| NLM Institutional Grants for Research Training in Biomedical Informatics, Data Science, and AI (T15 Independent Clinical Trial Not Allowed) | RFA-LM-28-001 | NIH | 93.398 | February 11, 2027 | $775,000 | Same assistance listing 93.398 as 106 awards here |
| Short Courses on Innovative Methodologies and Approaches in the Behavioral and Social Sciences (R25 Clinical Trials Not Allowed) | RFA-OD-25-003 | NIH | 93.398 | April 9, 2027 | $200,000 | Same assistance listing 93.398 as 106 awards here |
| Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Required) | PA-24-175 | NIH | 93.398 | May 7, 2027 | Not listed | Same assistance listing 93.398 as 106 awards here |
| Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed) | PA-24-176 | NIH | 93.398 | May 7, 2027 | Not listed | Same assistance listing 93.398 as 106 awards here |
| Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Required) | PA-24-190 | NIH | 93.398 | May 7, 2027 | Not listed | Same assistance listing 93.398 as 106 awards here |
| Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Not Allowed) | PA-24-191 | NIH | 93.398 | May 7, 2027 | Not listed | Same assistance listing 93.398 as 106 awards here |
| NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Required) | PA-24-193 | NIH | 93.398 | May 7, 2027 | Not listed | Same assistance listing 93.398 as 106 awards here |
| Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Required) | PA-24-181 | NIH | 93.398 | May 8, 2027 | Not listed | Same assistance listing 93.398 as 106 awards here |
| Successor-in-Interest (Type 6 Parent Clinical Trial Optional) | PA-24-253 | NIH | 93.398 | July 17, 2027 | Not listed | Same assistance listing 93.398 as 106 awards here |
| Investigator-Focused Award (Parent R35) | PAR-28-037 | NIH | 93.398 | October 4, 2027 | Not listed | Same assistance listing 93.398 as 106 awards here |
| NCI Pathway to Independence Award (K99/R00 Clinical Trial Not Allowed) | PAR-25-135 | NIH | 93.398 | October 14, 2027 | Not listed | Same assistance listing 93.398 as 106 awards here |
| NCI Pathway to Independence Award (K99/R00 Clinical Trial Required) | PAR-25-313 | NIH | 93.398 | October 14, 2027 | Not listed | Same assistance listing 93.398 as 106 awards here |
Topics of its NIH awards
- Cancer
- Genetics
- Rare Diseases
- Clinical Research
- Biotechnology
- Human Genome
- Cancer Genomics
- Orphan Drug
- Immunotherapy
- Translational Research
- Hematology
- Prevention
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.